<SEC-DOCUMENT>0001193125-13-333579.txt : 20130814
<SEC-HEADER>0001193125-13-333579.hdr.sgml : 20130814
<ACCEPTANCE-DATETIME>20130814061632
ACCESSION NUMBER:		0001193125-13-333579
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20130814
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130814
DATE AS OF CHANGE:		20130814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MANNKIND CORP
		CENTRAL INDEX KEY:			0000899460
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133607736
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50865
		FILM NUMBER:		131034853

	BUSINESS ADDRESS:	
		STREET 1:		28903 NORTH AVE PAINE
		CITY:			VALENCIA
		STATE:			CA
		ZIP:			91355
		BUSINESS PHONE:		6617755300

	MAIL ADDRESS:	
		STREET 1:		28903 NORTH AVE PAINE
		CITY:			VALENCIA
		STATE:			CA
		ZIP:			91355
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d584757d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>of the Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): August&nbsp;14, 2013 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>MannKind Corporation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="31%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-50865</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13-3607736</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>28903 North Avenue Paine Valencia, California</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>91355</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (661)&nbsp;775-5300 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report.) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form&nbsp;8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">On
August&nbsp;14, 2013, we announced positive preliminary results from our two recently-completed Phase 3 clinical studies of
AFREZZA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (insulin human [rDNA origin]) Inhalation Powder. The two studies were conducted based upon our
discussions with the U.S. Food and Drug Administration (FDA) following our receipt of a Complete Response letter in January 2011. In the Complete Response letter, the FDA requested that we conduct two clinical studies with our next generation (Gen2)
inhaler (also known as Dreamboat&#153;); one in patients with type 1 diabetes and one in patients with type 2 diabetes, with at least one of the studies including a treatment group using our first generation inhaler (also known as MedTone) in order
to obtain a head-to-head comparison of the pulmonary safety data for the two devices. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Study 171 </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Study 171 was an open-label study involving 518 patients with type 1 diabetes on basal/bolus insulin therapy who were studied at sites in the United
States, Russia, Ukraine and Brazil. After a four-week run-in period to optimize their basal insulin, patients entered a 24-week treatment period in which they were randomized in one of three ways: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Continuing on subcutaneous insulin aspart in combination with a basal insulin (170 patients); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Switching to AFREZZA administered using the Gen2 inhaler in combination with their basal insulin (174 patients); or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Switching to AFREZZA administered using the MedTone inhaler in combination with their basal insulin (174 patients). </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The treatment period consisted of 12 weeks of prandial insulin optimization with continued basal titration followed by a 12-week period during which
subjects maintained stable doses of insulin (prandial and basal). There was also a follow-up visit four weeks after completion of the treatment period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Over the 24-week treatment period of this study, A1c levels decreased comparably in the AFREZZA-Gen2 group (-0.21%) and the insulin aspart group (-0.40%). The 95% confidence interval (0.02% to 0.36%) of
the between-group difference did not exceed the predetermined threshold of 0.40%, thereby establishing non-inferiority between AFREZZA-Gen2 and insulin aspart, which was the primary endpoint of the study. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">There was a significant difference in fasting blood glucose (FBG) levels in the AFREZZA-Gen2 group compared to the insulin aspart group in Study 171. In
the AFREZZA-Gen2 group, mean FBG levels decreased by 25.3 mg/dL by the end of the treatment period whereas the insulin aspart group experienced an increase of 10.2 mg/dL in FBG levels over the same period (p=0.0027). After the four-week follow-up
period, during which all patients received insulin aspart and a basal insulin, there was no longer any difference in FBG levels between the treatment groups, demonstrating that this effect on FBG levels was attributable to AFREZZA therapy.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Significantly less total hypoglycemia was observed in the AFREZZA-Gen2 group (9.80 events per subject-month) compared to the insulin aspart
group (13.97 events per subject-month; p&lt;0.0001). The event rate of severe hypoglycemia was also lower in the AFREZZA-Gen2 group (8.05 events per subject-month) than in the insulin aspart group (14.45 events per subject-month); however, this
difference was not statistically significant (p=0.1022). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The proportion of subjects achieving A1c target levels <FONT
STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>7.0% or <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>6.5% at the end of the 24-week treatment period was less in the AFREZZA-Gen2 group than in the insulin aspart group; however, among patients who achieved
A1c levels <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>7.0% and <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>6.5% at the end of the 24-week treatment period, the event rates for overall hypoglycemia (mild, moderate and severe) were all
significantly lower in the AFREZZA-Gen2 group than in the insulin aspart group. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">There was also a significant difference in weight outcomes in
Study 171. Patients in the AFREZZA-Gen2 group lost an average of 0.39 kg over the treatment period compared to an average gain of 0.93 kg in the insulin aspart group (p=0.0102). </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The main safety objective of Study 171 was to compare changes in FEV1 (forced expiratory volume in one
second) from randomization to week 24 between the AFREZZA-Gen2 and AFREZZA-MedTone groups. Over this period, there was an insignificant difference of 0.01 L in mean change in FEV1 between the two AFREZZA groups (p=0.5364). Over the same 24-week
treatment period, the decrease in FEV1 seen in the AFREZZA-Gen2 group was slightly greater than that seen in the aspart group (0.03 L). After cessation of the treatment period, FEV1 values in both AFREZZA groups increased, so that by the follow-up
visit at week 28 there were virtually no differences in FEV1 among the three treatment groups. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, treatment with AFREZZA was
well-tolerated over 24 weeks by subjects with type 1 diabetes. The incidence of serious adverse events related to study drug was similar in the AFREZZA-Gen2 (2.3%), AFREZZA-MedTone (2.9%)&nbsp;and insulin aspart (1.8%)&nbsp;groups. There were no
serious cardiovascular events reported in this study. The most common drug-related adverse event was cough, reported by 30.5% of AFREZZA-Gen2 patients, 20.8% of AFREZZA-MedTone patients and 0% of insulin aspart patients. Cough was predominantly dry,
intermittent, and usually occurred within 10 minutes of inhalation. The incidence of cough was highest during the first week of the treatment period and diminished quickly thereafter. The discontinuation rate due to cough was low (AFREZZA-Gen2:
5.7%; AFREZZA-MedTone: 2.9%; insulin aspart: 0%). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;14, 2013 we issued a press release announcing the results of Study 171, a
copy of which is attached as Exhibit 99.1 to this current report. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Study 175 </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Study 175 was a double-blind, placebo-controlled study involving 353 patients with type 2 diabetes whose disease was inadequately controlled on metformin with or without a second or third oral medication.
Patients were studied at sites in the United States, Russia, Ukraine and Brazil. After a six-week run-in period during which all patients received dietary counseling and initiated blood glucose monitoring while continuing their oral medications,
patients entered a 24-week treatment period in which they were randomized to one of two groups where, in addition to their oral medication, they received either: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AFREZZA Inhalation Powder, administered using the Gen2 inhaler (177 patients); or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Technosphere Inhalation Powder (placebo), administered using the Gen2 inhaler (176 patients). </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The treatment period consisted of 12 weeks of prandial insulin titration followed by 12 weeks of relatively stable dosing. Subjects could not adjust or
alter the doses of their oral medications during the study without discussion between the principal investigator and the medical monitor. There was also a safety follow-up visit four weeks after completion of the treatment period, during which all
subjects returned to oral therapy only. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The primary endpoint of the study was the mean change in A1c levels from baseline to week 24 between
the two groups. Over the 24-week treatment period, mean A1c levels decreased by 0.82% in the AFREZZA group compared to a decrease of 0.42% in the comparator oral-therapy group. The between-group difference in change in mean A1c levels was
statistically significant (p&lt;0.0001), thereby establishing the superiority of AFREZZA over the comparator oral-therapy treatment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A
significantly greater percentage of patients in the AFREZZA group reached specified A1c target levels than in the comparator oral-therapy group. After 24 weeks of treatment, 37.7% of patients in the AFREZZA group achieved A1c levels below 7.0%
compared to only 19.0% of patients in the comparator oral-therapy group (p=0.0005), and 15.9% of patients in the AFREZZA group achieved A1c levels below 6.5% compared to only 4.2% of the patients receiving only oral therapy (p=0.0021). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the treatment period, postprandial glucose excursions were reduced in the AFREZZA group compared to those in the comparator oral-therapy group. By
week 24, mean blood glucose levels did not exceed 170.2 mg/dL postprandially in the AFREZZA group whereas mean blood glucose levels reached as high as 194.7 mg/dL postprandially in the comparator oral-therapy group. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Over the treatment period, mean fasting blood glucose levels decreased moderately in the AFREZZA group by
11.2 mg/dL compared to a decrease of 3.8 mg/dL in the comparator oral-therapy group. This difference was not statistically significant (p=0.1698). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Patients in the AFREZZA group gained an average of 0.49 kg over the treatment period compared to an average loss of 1.13 kg by patients in the comparator oral-therapy group (p&lt;0.0001). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As expected, the incidence of mild and moderate hypoglycemia was higher in the AFREZZA group (67.2% of patients) compared to the comparator oral-therapy
group (30.1% of patients; p&lt;0.0001). However, there was not a significant difference in the incidence of severe hypoglycemia, which was reported in nine (5.1%)&nbsp;AFREZZA patients compared to three (1.7%)&nbsp;oral-therapy patients (p=0.0943).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, treatment with AFREZZA was well-tolerated over 24 weeks by subjects with type 2 diabetes. The incidence of serious adverse events
was lower in the AFREZZA group (2.8%)&nbsp;compared to the comparator oral-therapy group (5.1%). The incidence of serious cardiovascular events was low overall and balanced between the groups (AFREZZA: 2 events; oral therapy: 3 events). Similarly,
the incidence of adverse events resulting in discontinuation was low overall and balanced between the treatment groups (AFREZZA: 4.0%; oral therapy: 5.1%). The most common adverse event was cough, occurring with comparable incidence in both the
AFREZZA (23.7%)&nbsp;group and the oral therapy (19.9%)&nbsp;group (who were also taking a placebo powder). Cough was predominantly dry, intermittent, and usually occurred within 10 minutes of inhalation. The incidence of cough in both treatment
groups was highest during the first week of the treatment period and diminished thereafter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;14, 2013 we issued a press release
announcing the results of Study 175, a copy of which is attached as Exhibit 99.2 to this current report. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The results of both Study 171 and
Study 175 contained in this current report are preliminary and subject to additional analysis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We anticipate that the results of Study 171
and Study 175 will form the basis of an amendment to our new drug application for AFREZZA, which we expect to submit to the FDA early in the fourth quarter of 2013. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>(d)&nbsp;Exhibits.</I> The following exhibits are filed herewith: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of MannKind Corporation dated August&nbsp;14, 2013, reporting MannKind&#146;s results from a Phase 3 clinical study of AFREZZA in patients with type 1
diabetes.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of MannKind Corporation dated August&nbsp;14, 2013, reporting MannKind&#146;s results from a Phase 3 clinical study of AFREZZA in patients with type 2
diabetes.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-Looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This current report contains forward-looking statements, including statements related to the results of clinical studies and our expected preparation and timing of regulatory submissions, that involve
risks and uncertainties. Words such as &#147;believes&#148;, &#147;anticipates&#148;, &#147;plans&#148;, &#147;expects&#148;, &#147;intend&#148;, &#147;will&#148;, &#147;goal&#148;, &#147;potential&#148; and similar expressions are intended to
identify forward-looking statements. These forward-looking statements are based upon our current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of
these risks and uncertainties, which include, without limitation, difficulties or delays in obtaining regulatory feedback or completing and analyzing the results of clinical studies, completion of further statistical analysis of the results of Study
171 and Study 175, whether the data from Study 171 and Study 175 will satisfy all requirements of the FDA and will be sufficient to support approval of an amended new drug application for AFREZZA, the timing of regulatory review and decisions, our
ability to manage our existing cash resources or raise additional cash resources, stock price volatility and other risks detailed in our filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended
December&nbsp;31, </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
2012, periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this
current report. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this
current report. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MANNKIND CORPORATION</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ David Thomson, Ph.D., J.D.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">David Thomson, Ph.D., J.D.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate Vice President, General Counsel and Secretary</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: August&nbsp;14, 2013 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d584757dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g584757ex99_1logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Contact: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Matthew Pfeffer </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">661 775-5300 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">mpfeffer@mannkindcorp.com </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>in Patients with Type 1 Diabetes </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>VALENCIA, California (Business Wire) &#150; August&nbsp;14, 2013 &#150; MannKind Corporation (Nasdaq: MNKD)</B> today announced positive preliminary results from Study 171, a Phase 3 clinical study of
AFREZZA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (insulin human [rDNA origin]) Inhalation Powder, an investigational, ultra rapid-acting mealtime
insulin therapy, administered using MannKind&#146;s next-generation (Gen2) inhaler (also known as the Dreamboat&#153; inhaler), in patients with type 1 diabetes. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Highlights </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AFREZZA-Gen2, compared to insulin aspart, showed: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-inferior decreases in A1c levels; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Significantly less hypoglycemia; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Significant decreases in fasting blood glucose levels; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Significant weight advantage. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, the changes in pulmonary function observed in the AFREZZA-Gen2 group were no different than those observed in an AFREZZA treatment group that utilized MannKind&#146;s first-generation
(MedTone) inhaler. This finding will facilitate bridging the Gen2 inhaler to the pulmonary safety data that was collected in earlier clinical studies using the MedTone inhaler. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;We are pleased that Study 171 met its primary endpoint of non-inferiority, by demonstrating that AFREZZA produces A1c reductions comparable to insulin aspart,&#148; stated Alfred Mann, Chairman and
Chief Executive Officer of MannKind Corporation. &#147;Importantly, this study also established a bridge between the Gen2 inhaler and the large body of pulmonary safety data that was previously collected for AFREZZA using the MedTone inhaler.
Consistent with previous studies of AFREZZA, including a two-year safety study involving 2,035 subjects, the use of AFREZZA was associated with a clinically insignificant decrease in lung function that appeared at the onset of therapy, did not
progress during therapy and resolved fully upon cessation of therapy. Based on the results of this study, we believe that AFREZZA can be used to achieve glycemic control that is comparable to the current standard of care while at the same time
offering potential advantages in terms of lower fasting blood glucose levels, weight neutrality and a lower overall risk of hypoglycemia.&#148; </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Study 171 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Study 171 was an open-label study involving 518 patients with type 1 diabetes on basal/bolus insulin therapy who were studied at sites in the United States, Russia, Ukraine and Brazil. After a four-week
run-in period to optimize their basal insulin, patients entered a 24-week treatment period in which they were randomized in one of three ways: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Continuing on subcutaneous insulin aspart in combination with a basal insulin (170 patients); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Switching to AFREZZA administered using the Gen2 inhaler in combination with their basal insulin (174 patients); or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Switching to AFREZZA administered using the MedTone inhaler in combination with their basal insulin (174 patients). </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The treatment period consisted of 12 weeks of prandial insulin optimization with continued basal titration followed by a 12-week period during which
subjects maintained stable doses of insulin (prandial and basal). There was also a follow-up visit four weeks after completion of the treatment period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Over the 24-week treatment period of this study, A1c levels decreased comparably in the AFREZZA-Gen2 group (-0.21%) and the insulin aspart group (-0.40%). The 95% confidence interval (0.02% to 0.36%) of
the between-group difference did not exceed the predetermined threshold of 0.40%, thereby establishing non-inferiority between AFREZZA-Gen2 and insulin aspart, which was the primary endpoint of the study. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Results </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">There was a significant
difference in fasting blood glucose (FBG) levels in the AFREZZA-Gen2 group compared to the insulin aspart group. In the AFREZZA-Gen2 group, mean FBG levels <U>decreased</U> by 25.3 mg/dL by the end of the treatment period whereas the insulin aspart
group experienced an <U>increase</U> of 10.2 mg/dL in FBG levels over the same period (p=0.0027). After the four-week follow-up period, during which all patients received insulin aspart and a basal insulin, there was no longer any difference in FBG
levels between the treatment groups, demonstrating that this effect on FBG levels was attributable to AFREZZA therapy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Significantly less
total hypoglycemia was observed in the AFREZZA-Gen2 group (9.80 events per subject-month) compared to the insulin aspart group (13.97 events per subject-month; p&lt;0.0001). The event rate of severe hypoglycemia was also lower in the AFREZZA-Gen2
group (8.05 events per subject-month) than in the insulin aspart group (14.45 events per subject-month); however, this difference was not statistically significant (p=0.1022). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The proportion of subjects achieving A1c target levels <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>7.0% or <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>6.5% at the end of the 24-week treatment period
was less in the AFREZZA-Gen2 group than in the insulin aspart group; however, among patients who achieved A1c levels <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>7.0% and <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>6.5% at the end of the 24-week
treatment period, the event rates for overall hypoglycemia (mild, moderate and severe) were all significantly lower in the AFREZZA-Gen2 group than in the insulin aspart group. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There was also a significant difference in weight outcomes. Patients in the AFREZZA-Gen2 group <U>lost</U> an average of 0.39 kg over the treatment period compared to an average <U>gain</U> of 0.93 kg in
the insulin aspart group (p=0.0102). </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The main safety objective of this study was to compare changes in FEV</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.4ex">1</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (forced expiratory volume in one second) from randomization to week 24
between the AFREZZA-Gen2 and AFREZZA-MedTone groups. Over this period, there was an insignificant difference of 0.01 L in mean change in FEV</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUB
STYLE="vertical-align:baseline; position:relative; top:.4ex">1</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> between the two AFREZZA groups (p=0.5364). Over the same 24-week treatment period, the decrease in FEV</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.4ex">1</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> seen in the AFREZZA-Gen2 group was slightly greater than that seen in
the aspart group (0.03 L). After cessation of the treatment period, FEV</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.4ex">1</SUB></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> values in both AFREZZA groups increased, so that by the follow-up visit at week 28 there were virtually no differences in FEV</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUB
STYLE="vertical-align:baseline; position:relative; top:.4ex">1</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> among the three treatment groups. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In general, treatment with AFREZZA was well-tolerated over 24 weeks by subjects with type 1 diabetes. The incidence of serious adverse events related to study drug was similar in the AFREZZA-Gen2 (2.3%),
AFREZZA-MedTone (2.9%)&nbsp;and insulin aspart (1.8%)&nbsp;groups. There were no serious cardiovascular events reported in this study. The most common drug-related adverse event was cough, reported by 30.5% of AFREZZA-Gen2 patients, 20.8% of
AFREZZA-MedTone patients and 0% of insulin aspart patients. Cough was predominantly dry, intermittent, and usually occurred within 10 minutes of inhalation. The incidence of cough was highest during the first week of the treatment period and
diminished quickly thereafter. The discontinuation rate due to cough was low (AFREZZA-Gen2: 5.7%; AFREZZA-MedTone: 2.9%; insulin aspart: 0%). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">These preliminary results are subject to further analysis. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About AFREZZA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AFREZZA<B><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;
</SUP></FONT></B> is a novel, ultra rapid-acting mealtime insulin therapy being developed by MannKind Corporation for the treatment of adult patients with type 1 or type 2 diabetes for the control of hyperglycemia. It is a drug-device combination
product, consisting of AFREZZA Inhalation Powder, pre-metered into single-use cartridges, and a light, discreet and easy-to-use inhaler. Administered at the start of a meal, AFREZZA dissolves immediately upon inhalation and delivers insulin quickly
to the bloodstream. Peak insulin levels are achieved within 12 to 14 minutes of administration, effectively mimicking the release of meal-time insulin observed in healthy individuals, but which is absent in patients with diabetes. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About MannKind Corporation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product candidate, AFREZZA<B><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></B>, has completed Phase 3 clinical trials. MannKind maintains a website at www.mannkindcorp.com to which MannKind
regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its
reports with the Securities and Exchange Commission or posts certain other information to the website. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-Looking Statements
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains forward-looking statements, including statements related to the results of clinical studies, the bridging to
an earlier clinical program, the potential use of AFREZZA to achieve glycemic control in type 1 diabetes patients that is comparable </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to the current standard of care, and the potential advantages of AFREZZA over current treatments, that involve risks and uncertainties. Words such as &#147;believes&#148;,
&#147;anticipates&#148;, &#147;plans&#148;, &#147;expects&#148;, &#147;intend&#148;, &#147;will&#148;, &#147;goal&#148;, &#147;potential&#148; and similar expressions are intended to identify forward-looking statements. These forward-looking
statements are based upon the Company&#146;s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include,
without limitation, difficulties or delays in obtaining regulatory feedback or completing and analyzing the results of clinical studies, completion of further statistical analysis of the results of Study 171, whether the data from Study 171, as well
as Study 175, the Phase 3 clinical study of AFREZZA in type 2 diabetes patients, will satisfy all requirements of the Food and Drug Administration and will be sufficient to support approval of an amended new drug application for AFREZZA, the timing
of regulatory review and decisions, MannKind&#146;s ability to manage its existing cash resources or raise additional cash resources, stock price volatility and other risks detailed in MannKind&#146;s filings with the Securities and Exchange
Commission, including the Annual Report on Form 10-K for the year ended December&nbsp;31, 2012 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of
the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances
after the date of this press release. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d584757dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.2 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g584757ex99_2logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Contact: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Matthew Pfeffer </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">661 775-5300 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">mpfeffer@mannkindcorp.com </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>in Patients with Type 2 Diabetes </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>VALENCIA, California (Business Wire) &#150; August&nbsp;14, 2013 &#150; MannKind Corporation (Nasdaq: MNKD)</B> today announced positive preliminary results from Study 175, a Phase 3 clinical study of
AFREZZA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (insulin human [rDNA origin]) Inhalation Powder, an investigational, ultra rapid-acting mealtime
insulin therapy administered using MannKind&#146;s next-generation (Gen2) inhaler (also known as the Dreamboat&#153; inhaler), in patients with type 2 diabetes. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Highlights </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AFREZZA combined with oral therapy, compared to oral therapy alone, showed:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Superior reductions in A1c levels; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Significantly more patients reached A1c target levels; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reduced postprandial glucose excursions; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">No significant difference in the incidence of severe hypoglycemia. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;We are pleased that Study 175 met its primary endpoint of demonstrating that AFREZZA, when added to a regimen of metformin with or without a second or third oral medication, produced superior A1c
reductions compared to oral therapy alone,&#148; stated Alfred Mann, Chairman and Chief Executive Officer of MannKind Corporation. &#147;In this study, significantly greater numbers of patients in the AFREZZA group reached the American Diabetes
Association goal of A1c levels less than or equal to 7.0% and the American Association of Clinical Endocrinologists goal of less than or equal to 6.5%. As well, the AFREZZA group exhibited noticeably reduced postprandial glucose excursions. As would
be expected in a study that added insulin to an oral treatment regimen, hypoglycemic events were more frequent in the AFREZZA group, but no AFREZZA patient discontinued because of hypoglycemic adverse events. Based on the results of this study, we
believe that AFREZZA can be used to improve glycemic control in insulin-naive type 2 diabetes patients that are not adequately controlled on conventional oral medications &#150; a potentially large and underserved patient population.&#148;
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Study 175 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Study 175 was a
double-blind, placebo-controlled study involving 353 patients with type 2 diabetes whose disease was inadequately controlled on metformin with or without a second or third oral medication. Patients were studied at sites in the United States, Russia,
Ukraine and Brazil. After a six-week run-in period during which all patients received dietary counseling and initiated blood glucose monitoring while continuing their oral medications, patients entered a 24-week treatment period in which they were
randomized to one of two groups where, in addition to their oral medication, they received either: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AFREZZA Inhalation Powder, administered using the Gen2 inhaler (177 patients); or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Technosphere Inhalation Powder (placebo), administered using the Gen2 inhaler (176 patients). </FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The treatment period consisted of 12 weeks of prandial insulin titration followed by 12 weeks of relatively
stable dosing. Subjects could not adjust or alter the doses of their oral medications during the study without discussion between the principal investigator and the medical monitor. There was also a safety follow-up visit four weeks after completion
of the treatment period, during which all subjects returned to oral therapy only. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The primary endpoint of the study was the mean change in
A1c levels from baseline to week 24 between the two groups. Over the 24-week treatment period, mean A1c levels decreased by 0.82% in the AFREZZA group compared to a decrease of 0.42% in the comparator oral-therapy group. The between-group difference
in change in mean A1c levels was statistically significant (p&lt;0.0001), thereby establishing the superiority of AFREZZA over the comparator oral-therapy treatment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Other Results </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A significantly greater percentage of patients in the AFREZZA group reached
specified A1c target levels than in the comparator oral-therapy group. After 24 weeks of treatment, 37.7% of patients in the AFREZZA group achieved A1c levels below 7.0% compared to only 19.0% of patients in the comparator oral-therapy group
(p=0.0005), and 15.9% of patients in the AFREZZA group achieved A1c levels below 6.5% compared to only 4.2% of the patients receiving only oral therapy (p=0.0021). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During the treatment period, postprandial glucose excursions were reduced in the AFREZZA group compared to those in the comparator oral-therapy group. By week 24, mean blood glucose levels did not exceed
170.2 mg/dL postprandially in the AFREZZA group whereas mean blood glucose levels reached as high as 194.7 mg/dL postprandially in the comparator oral-therapy group. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Over the treatment period, mean fasting blood glucose levels decreased moderately in the AFREZZA group by 11.2 mg/dL compared to a decrease of 3.8 mg/dL in the comparator oral-therapy group. This
difference was not statistically significant (p=0.1698). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patients in the AFREZZA group gained an average of 0.49 kg over the treatment period
compared to an average loss of 1.13 kg by patients in the comparator oral-therapy group (p&lt;0.0001). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As expected, the incidence of mild and
moderate hypoglycemia was higher in the AFREZZA group (67.2% of patients) compared to the comparator oral-therapy group (30.1% of patients; p&lt;0.0001). However, there was not a significant difference in the incidence of severe hypoglycemia, which
was reported in nine (5.1%)&nbsp;AFREZZA patients compared to three (1.7%)&nbsp;oral-therapy patients (p=0.0943). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, treatment with
AFREZZA was well-tolerated over 24 weeks by subjects with type 2 diabetes. The incidence of serious adverse events was lower in the AFREZZA group (2.8%)&nbsp;compared to the comparator oral-therapy group (5.1%). The incidence of serious
cardiovascular events was low overall and balanced between the groups (AFREZZA: 2 events; oral therapy: 3 events). </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Similarly, the incidence of adverse events resulting in discontinuation was low overall and balanced between the treatment groups (AFREZZA: 4.0%; oral therapy: 5.1%). The most common adverse
event was cough, occurring with comparable incidence in both the AFREZZA (23.7%)&nbsp;group and the oral therapy (19.9%)&nbsp;group (who were also taking a placebo powder). Cough was predominantly dry, intermittent, and usually occurred within 10
minutes of inhalation. The incidence of cough in both treatment groups was highest during the first week of the treatment period and diminished thereafter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">These preliminary results are subject to further analysis. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About AFREZZA<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">AFREZZA<B><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></B> is a novel, ultra rapid-acting mealtime insulin
therapy being developed by MannKind Corporation for the treatment of adult patients with type 1 or type 2 diabetes for the control of hyperglycemia. It is a drug-device combination product, consisting of AFREZZA Inhalation Powder, pre-metered into
single-use cartridges, and a light, discreet and easy-to-use inhaler. Administered at the start of a meal, AFREZZA dissolves immediately upon inhalation and delivers insulin quickly to the bloodstream. Peak insulin levels are achieved within 12 to
14 minutes of administration, effectively mimicking the release of meal-time insulin observed in healthy individuals, but which is absent in patients with diabetes. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About MannKind Corporation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">MannKind Corporation (Nasdaq: MNKD)
focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product candidate, AFREZZA<B><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></B>, has completed Phase 3 clinical trials. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as
well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission
or posts certain other information to the website. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-Looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This press release contains forward-looking statements, including statements related to the results of clinical studies, the potential use of AFREZZA to improve glycemic control in insulin-naive type 2
diabetes patients who can no longer be adequately controlled on conventional oral medications, and the potential market opportunity for such use, that involve risks and uncertainties. Words such as &#147;believes&#148;, &#147;anticipates&#148;,
&#147;plans&#148;, &#147;expects&#148;, &#147;intend&#148;, &#147;will&#148;, &#147;goal&#148;, &#147;potential&#148; and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the
Company&#146;s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation,
difficulties or delays in obtaining regulatory feedback or completing and analyzing the results of clinical studies, completion of further statistical analysis of the results of Study 175, whether the data from Study 175, as well as Study 171, the
Phase 3 clinical study of AFREZZA in type 1 diabetes patients, will satisfy all requirements of the Food and Drug Administration and will be sufficient to support approval of an amended new drug application for AFREZZA, the timing of regulatory
review and decisions, MannKind&#146;s ability to manage its existing cash resources or raise additional cash resources, stock price volatility and other risks detailed in MannKind&#146;s filings with the Securities and Exchange Commission, including
the Annual Report on Form 10-K for the year ended December&nbsp;31, 2012 and periodic reports on Form 10-Q and Form 8-K. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their
entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g584757ex99_1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g584757ex99_1logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`2@#A`P$1``(1`0,1`?_$`+,``0`!`P4!`0``````
M```````)!0@*`@,$!@<!"P$!``$%`0$!``````````````8#!`4'"`(!"1``
M``8"`0($!`$)!0D!`````0(#!`4&``<($1(A$Q0),2(R%3-!46%Q0B,6%PJ!
MD5*28['!@M*3TR1451@1``$"!`0$!`0""0,%`0````$"`P`1!`4A,1(&05$3
M!V%Q@2*1,A05H4+PL<'14B,S%@AB<B3A\8+"-#;_V@`,`P$``A$#$0`_`,Q;
ME#ONT5*P:YX^:53CG._MV2J4?`R$F@,A"ZHI2(K'M&V+*S(<#OQAHEDZ&'8&
M`4Y&43*18Q4"JFR1;;L#-=0OWZOPL=&)IX%:Y3#8)PF<)\ICGA&K]>7J-QJV
MV\`W>J5I5R2DF14?Q_&+FM;T>"UA54:U$JR+LB:[N5FI^;=*2,_9IU^)7$U:
M;+)*%3]7-S3L!67,!2)EZ@1,A$B%*7`U%T<NU5J<3^4!(`DE*!/2E(&0&,AZ
MXDQFV:2FM5-)!]LRI1XE1S/ZH[+&V2O6$CG[!.0\UZ)44'OV>28R8,UR@(BB
M[]$NMZ=4/\)Q*.4U-O,.)2XVKI%4IR.!^$>DU+-0@I;4"2,9$'#CD8CIY,;/
M-P%L$!R$['1N+-YOL?5^1U99MQ<):JL=XE!1@>05:1*=,S.&=61Z1K;VA3"F
MNFX3?HD!PDL5>:;?M#F^D/69'_Z&G;G2Y?S`C-'^X3!;]03*(G?JU&TULW%H
M`6):I/\`-)/YO7&8R_"))(V2CY-BSD(MVVD(^19MY"/?LETW+-\Q=HIN&KQL
MY2,9)=NY06*<ABB)3%,`@/00R$]!]ASZ6J!#[9(((D9@R(/B"#.)>A370^HI
MR%-*D9C+$3'X14R=.@]/RB.>&M7NU?Q'X15``&'&-6580Q"&(0Q"&(0Q"&(0
MQ"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(1`EQ)V4UVES9AMQ3YCKNM
MNQVTGU45=J]Y8J,"%ADZ)","G$00(UU[#+]J)!`OGN')Q`3JJ".^=X6)5EV%
M]GIP2*5Q)=`XE1`).6&J-=6)WZBXHNE1_6?F">0E@$\N7&+A_<HO]F(YUIJ"
M.EI")JUIBK)<+NC%.5V"]I8P+^%BH6L/WS)5!X6OB^ESN7S<IBD>E2324ZIB
M8IHGVPLM'<4U%S*-3K`24!6(!(,\..6'+&,ON*L6*I-M)_XRFP21\V)(S].4
M1@1$C)ZL=EV!K!=M2+E4&JTK%R44B6.9OD(M,7CBO61FU\IG,5V7;(G:KHNB
M*E335$Q!(8I3!NVY4=%<*)5OK*9DI<2`2E,E)G/W).,E)S!X&(Z4+M2354BR
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MC%4@H.WZJ4A(6+>$AME:+M+:&CWK@!310MVM7AXUFF_`@_-#V*+3*F\(/0%X
MY\<0^(#G6R*FCW'2/O/>Z@KV_43&!EP(GZ&-54K;S%O;I$X5U,J:QE\.)RY"
M)?\`85$A.>^E=<[5UU*Q]1V-6@DT&K.QE5691DHX]$RO^K[NE&^8];HI/X]%
M1-PD4RB2J#=P1-1)02GT3:[I6[!O550520:!0"3I.)$U:5#(2D92\\9C&5O4
M2;M1)K&B/J<A/TP/K%NU(]N_<-EG63/;;RFU/7Z#QDI9V]9GGUJL]MBFZP+N
MJW'&/"0K&OLY@J?D.GAC*."H',"293#U"7W_`+I6E%&I5J2^:Q:-`U)"0"9B
M?S$F4Y@<\Y194VVZ^H4*>X*0*2<\%$DRX9#U,0S_`-0KSTC]CW6$X/ZKDFZU
M*U#,,+#N*0CC%%K);'9,S)0%*;"D86R[&D,'?G.B#\H22I4Q#JV'-N_XX]O*
MJVTSN^[PC_GU`G3`GGCJ/(*(20<2`.$XT5WNWM3UKR-DV]1^G;$GR,I92!GC
M(3PPB23^FSU9,5'AEL;9$LQ59-MR;GEI.N"L*X`_K],@XJHDDD$E@Z%;.)QJ
M_(4Q0`#BD(AX=!'6W^2EX17[Z;H]25)HZ8)5+&2BHF7CA(\/QB;]A;4_1[1=
MJ'1)NI>U(YR"98CAG&104``/#.>P04@C*4;T``P'./N?8^PQ"&(0Q"&(0Q"&
M(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(1"O[@NHCTJ^QN\H1ITJ
M^R%8VK;"\A(H-HB_-&H1],LSD.ANQ.WQ@EB'"AR]A7+=GW&#S!$=S=N+PJM0
MYMY2I.-S6B9X<1Z</#RB%WFG1;KNFN`/T[WM4.$_^L>)\7-]?_GK9PNIQWZ3
M4^QWT9$;"3-U]/6;`!TV%9V44#"KY:#8ADXZ9,(]19>2X./_`(@]<SO;:S&X
MK<54R3]UIDE1&6I/*?/`D>/G%"BJ'+?5:EG_`(KCD@.66,79>[9[A47P/XXO
MGU9?,7F^=IMY"M:9AU>QP#)X*!`E]BR#4G<8T%26;DBX"("1P].@B'7N-TAO
M:WMXYO[<J&GYIM-(=3TQ@2)%*)\U2/D)\91:]RM\)V58U/MB=:Z-+>(F)S!5
MSP_3*,#7CGHG9/,/D-2=-U)>3FKUM>Y*C8;*]ZOEXQF[=GDKM?;`J<W>9*-:
MG</5U!']\L`%`>Y0N=_[HW-0;%VR+NXA*;51(D$B0U$#`#S,AZQQEMVUU&\K
MNJC:457:J7/49D`'B>4H_3,T=J.G:!U'K;2]!:@RI^M:?#4^!1[2%56:P[0C
M=5\[$@=%'TBZ!1PN;]I94PCXCGY>7ZXUM]NM5=JM1+KBRLXSQ.0]!(#RCO\`
MM-+2VBW4UKIA)"$`?#,^ICUTGP^(>(B.6B#-`\HR4M)(/$F-?4,]1]AB$.N(
M3$,0CYU#\X?WXA'WKB$Q#J&?)B<N,(9]A#$(8A#&8F,H0Q"&(0Q"&(0Q"&(0
MQ"&(0ZAB$,0AB$,0CHNQJ'6=HTBRZ^N,:64K%MC%X:8:"82*"W<].QTU6`#'
M:R#!P4B[98O0Z#A,BA1`2AE:FJWK?6-U=,9/I4"#RE^S@?"+9YANO94P^/Y1
M'Z?",9_<<&?CQ*[(J&ZG[9!KK>+7E)2QOT#)QESURX;N$X2YM4C]R)OO;<AF
M+QJ3KVRQ540'H9,3=7;;JG=U4C"[:9O/I#93Q0X/FG\1*-95;S5L14.7$A%-
M3@G'\R,TR_&,77D_R6O_`"<V&A<+Q9)N9A:E7D*%K6-GW)G;BIZ[@W#H:]$F
M6*8@.7YVRI3/'`AYSE40\P3"'7.D-K;,L>TK7]"P`E]QP+J%?ZR9@GR,XY%W
M-N.MW;>%URYDHFBG').4OU1F+>P_[=CKC+II?DEM:$*RWEO:':K0\;(-13DM
M=ZF7\I]"P9TU@[F<[:U2DD9$`*!B$].B8.J9PSC3OWW%3N7<"]OVY059:$R4
MH&8<4"9Y&1`E*7!4_".JNT&R/[>M"+O4)E<:H`J!S`_83^KSB1KW!^;49P'T
M2SW=*ZYEMGHOM@5F@(5B#F&4$_,[LY)$Z+PKQ\V=H*`DI']OE@3N.90`#IXY
MK[MSL96_]P)L%-4ADI94[J(U`!)`YCGSB;;XW<QLNR?>WTZU!Q*)><_W1;%"
M>[SJZ8]O6S\^OY=3K5*J7-UKIYIDUCBE+2M?4K4RKK&L(S)&8-1<RC:12?%$
M6X&!'N#M$0S/N]G[G2[^;V4:D%QQCZCJ2]H;4#[B)\"F4I\?.,0ON;:U[/7O
M!I@K0VM36GCKD"1Y2CV;VZ_<,KGN`:JV+M5KK69TW'ZZOR]&E(VU66,F%5%T
M82-FG$HN];-HYO'MT"R'E&(H'4IR"/7,/W&[>W'8%_:L:JD/U#["'$Z4$@ZR
M0$A,R9F47NP]]TN]K,N^*:33L-J"25D8%(/APG%^-?OM%N"#Q[4;E5K4S8*F
M;R+FN6")FF[!4@&,9-XI'O%TVJI2@(_.)1Z9!:REK:)Y#%4TZPXL^W6V0%*Y
M`G&?A*)72W"DJ&BY3/,+IT$J*M6(]`(V5-C:\1<0K)2[TY)U8U54:\S&S017
M,\LW4%)=*&0^X>9*G15*)#%1`XE.`@/CGT6:[)#A+;I6A6H_RE32.9'#S,H^
MBOM+<DAZG#*_:/<,3R$<F2O-(@"2AYJW5F"+"MT'TT:8GHF,"&9.S@FU=RH/
M'J(QK9RH(%3.MV%.80`/'+9JEK:I`>HT+DL_-TYZIYC/$CC%=VJHZ4])QQD*
M;0)@J`D,9$\ARBQ7GS[A%4X+:RU;M->B/=O0FT=E0^O(M.K6>'C$FH3+%T_;
MSZ<FLA(,I".*1J(=J0AW]>O=X#D[V)L&KWI75MJ2Z:>HH*5=2H*;()#9`(E,
M9ZA*<0_>V\Z?:M!37!*6WZ2I?0R-)_,N<CQPP,XYA^>419N<##A-JK6LOLN=
MK]-0NN^-CQMA81]0T8T>D!2*@I\#-G2\[9I$JR0$9HG2.0[@G?T`#B0O8]11
M[*.[KG5):0JJ*&&R/>Y+-0Q$DCP!F,<(^#>=-5;E&V:&G+KCC`6ZX):43X'Q
M'ICA'8>+'-!#D1+<B&-HU?+Z2CM";45U@WGKK9H1:.V!Y;B1:)6.%<)@T3CF
M;A6.`I$%CG6$RI0^.6^XMF.6(6VKIG/JJFX4G6TH:.H`A)EF9RGGA'O;^YS=
M55].^VJF8H7NGJ+F!S&>$LHO"C;C4)67DZ]$6B`EIV%[/O,)&S<9(3$1YW:*
M8RD8U=JOF(*@8.WS4R]>OZ0R'.,UGT_U[S3U.T!I"G&R!,RRQ(X93B4LU-.I
M:J1#S;KND$IU:ER.1\N461\\O<"H'"#3SS:2D&UV[)Q.P:70IV@UBY5^,L4"
MI<EGJ;68F$EQ?KQK)IZ$1$BJ)15[@`HY--C;!O&[KA]K`4EU-(X]U.F0@I24
M`@8@3.H2,\@8B^[=[6[:U"BO*VE(#Z62@$:PI8,ICD-)G%\[*QL%*JRM3\Z,
M7&N(!&Q/5G*R9&T8Q5C2RCE9VY,)4B(,VYC"=0>A0`HCX!D.>IU?6BB2@K=4
MYTP!Q,Y`>IB5LO)-%]<2$M],.&?(B9^$06V3WV:45O>]DZLXD<B]O<6=76;^
M&+_R:K36!C:C'N4W*#15]%PTDH22D8I,SE)3SE%&_P"Z53,<$P.7KNZA[$7)
ME]NT76YTE+N5YN;-"9E02!.1D1(@"6`5D>4:B?[PT*7G;A:[<]46)E>EZI&4
MR<P)&?QB86B<A-/;`U!3=ZPU\KC?5M_@(BS5JUSLJPK[!PPFTBJ-D7*TNY:)
MLI)-4115;G-WI+$,0>H@.:?N%AN]JNM197*=]5:TLI6AL:E(4,SAP.!!C:%+
M?K356YJ\4M0GZ!T!25+,@0K\OFG(\H](6ME92C&<XM88-&"?E0]!+KRT>G%O
M0="4&@M'YG/HW(.!_#[#F%01^7KE@BFJEK+/2?34M`DH4@E>$AJ(SPGF><7J
MZBB%&:U;S1869!9(T8XZ9\\/PC8)=J6JH1,EKK:AEGK^-2[9Z*-ZB1BRB:2C
MDQ*[$5'L83Q<(_6@'U@7*B**M=<=9;9=);2%+DV<-64^1/Z&*;U?;V@AQ3M.
M`\-*9J&,N7,1OURV5>VQ_P!WJM@@[-%@NNU&3@)6.FXT'+4>UPCZZ-=.6P+-
MS]2G+W=Q3`("&4JFGK:/2AYMULG\JTD+5/E./K552U#?\M;3FC\R2"E/GRCB
M05]H]I=2<=6[A6;%)0JWD3#"#L$3+OXA?J4/3R+2/>.'#%7N,`=JA2CU'I\<
MJU-KKJ1`55,U*&W`"-25)EA,9RSCTU64KX"FG:=;LR`4J!G+/X<8WFERJ+]X
MBPCK-77[]RZ?,V[%C.1;EZZ=1:7FR;5%L@[.NNXC4S`=P0"B9$H]3@4,I*I:
ME+(>4VZW3ID"I:3I(.4CB)DC`Q[:J:!;Q;8=8-3^8!0)!S.6,<%KL;7\E..*
MI'7BHR%K:`87588V:&=V!N4`$>Y>&0>GD42@7YNIDP`"^/PRJ]0W-IKZHLO-
M4:9%3BVCI(.6/CP,4&;C;Z@I:6\QK6HI$E"<Q.<O$2BS[7_N":1V+R^V9P[A
MGB*5MUE5*W85;J[LU5/4+?(651FFA4::=&56?S5D8`['U*!"=R1DS%$O7)=<
M=@7:W[79W>Y,,U;FC1TU30/=)2I@`"2<_$1&+9O2W5>XJK:[8<U4R20Z7`=9
M$L/Q\<HK/#KF.MRKAMS3LUJ.?TJVU%M.<USUN$[$R!;.QA43+#<&KAFBW2C8
MIV7Z2JB)R^(B;/.[]H#:;UOI6ZDU3]PIDN@!L@S*0K1*9G*>8Y91[VKNA&X4
MUM2^S]*W2O%LZE3U"9`43(2G*+L8"\TJULG4K5;76K/%L%'#9](5Z<BYE@R6
M;&'U"3QZP=KMVQT.T1.4Y@$O0>OPR(U-+7424BL:<8<4?:E39!SE,`RGG$GI
M:NAK5+;IGVUH1\R9C`<XV?YBZ_%W"QP7:H#(6/S35V._B6$%Y/E;G$BYH5H#
MX5I4J"A1*84"J`!@Z?'*B[3=4E3G3<UH3-7\HS`\>6'./`N5J6E*.LP6U+*1
M[ABH$Y<\H[QU']/^7+76C^$_"+W2Y_$(XZ@F*F/CX]0#P#QZ]!^'C\>O3*;K
MS=.@U2`5?C/RCXVT'4!I9E+/&485']0QS?IVV=M0'%G681C]+2AI#^:U\8`!
MG;^V28,ERZN:/D#^6Y@ZT+9)U)I'$Q/N@I%Z`9!3KW)_C?L*XVFV.;RN15TJ
MPD--G\J0,')<U3P\!')/?3?%#6U#>V[<J263[U#\QGBB?&4OB8C3]OSC1+;#
MNT?O"58QIJ;J^R,)2LQU@:(R,#?+Y7GC*3:UZ4:+D5*ZK#!RF4DF<`\#&(F7
MYNN;>WS>Z>BMCVW6%ZJVN96@N`_(5C3.?!0G,'A$5[:[-J;[5&_NIT6^D(.@
MX$JS2?\`;AB.,?H1:!W-6M\:NK>Q*Z06/W!$S&P5Y=9([^HVR-[4+%5),J9A
M*1["O@,3J``59'RUB?NU"CGYJWRS56W[D[::R9>0HD$F>L3SF<Y\X[/L]P9N
M-('6I"6!`$I$<)</W2B(O^H$6!OPSUF=4Z:7;R[T$9(Z@@4OF?=Y8Q.X!_$+
MW%\0#XAUS<7^/:J.FWNXM?L;%N?$\C,%$L?4QJWO6RX[M5II*=8<NC0(E/V$
M&<N7G$13#CKL!+W5[)[<"*1@XXR?*R*Y\24:5$YFYZG$49Y98QH=,@`U^SJ3
MLB2/$1#L%X@0GQ#-M5-[H'>V3/<QPC^Z$TXMH<P!4J9#DTYS'M*5SPF2!C&K
MVK5=V=Y.['1-.W'%JJ=&G\L@4$*\@J?/#E'ANEMP:YUQ[67+E/9-`L^S8#8?
MN$A3B0=<V)8=95EG*K0",LV?;*N%71<RK:A-CQ_1=D!0%Z<"%ZEZ`8,Y=[?<
M[CWEM[UK6Q3/HL"5A3R$5!T(40=`60`Z9X+S'J8LK164]J[<5S%P;=6E-T`2
ME"E-`$@R4LI!*D"6*<CZ1<SPW&#J_NC7JO:]D-`1U.L_`[8[V9B.):5EC-!2
M\M$U5D94(TT[,2B=RL,$[.!7DJB84S+B)?E4*J&0W>+S]7VFIWJY58JO:OF*
MZ@H4X05I`(`/L$L@!E('C$CVLEL]T'443S+EJ-I*ND@J#864JGJ!3)7C/+$B
M+%T=,:O9>R9KOE*A#B3>D'S/;5&O;*-.RIYBM5E.:D!+7*_WOQ80\8=RB#DZ
M;=-,5'0BJ83&$<V6NZN5/>NLVWU$_P!ON[?6M:9C^J)24%2F,R)`REPB$HH0
M.U3=_>+OW1N\Z$$3_I\BG(X<8E4E])ZJY(>\-S<INZ:^G?:NSX.4*YA6Y.6D
M48ES9H_7M$",GI*-9/&[>2>Q*KY5PT,N4Y6[D_G$`#]!S3S%ZK]O]FZ!ZUJ0
MW7B_.`F22=&M0*<0?:9`2Y3E*<;*%+3WK?MPH*[6JW*LZ%)`)29A*I&8XB9/
MB93B+>[34U(>QQQ)(WFUGDA%\\KQ!50[^3\Y*.\B+G582.:K.3J%19,Y-SW$
M2#J5,#&Z!T\,W&TW;:?_`""NAF!;';`5N#4`%`J3J$^9EARC6M?4/U79VWK3
MK57)O(0#I)((3@?(`Q*+P68[0]KWW*F/'3D9=B72#Y\T"MW)#:+TK9`LOOE,
M'C]VS&555%XOV6!T_AB`<_1P5RR4`@=W0-2;_59>Z/;<;CL+70J+!6+;+*5`
M#I$2U%`$B=*-0^$;"V6BMV'O5%DO#BG1>*=*TND'YACI"CEBJ1$1Z;*>(H\'
M_>@6(Z2251]QO7Q_/!5(AT%BWR?$IA4Z_NEBG*`AU\0$/#QR?[?J*5.ZMFJ6
MJ33>W%:Y+E)>EB?EPPB)5JC_`&UN3ISUO7I($DXZ)NY?OB_8^HJKQO\`=<X4
MQO&F"+3[1MK@=?;99$6DQ*NW>P=B.M;7Q=E,VI60>NW$Y(24S'M%%5E1.85D
MR"`!VAT@#-ZKMS=M+M4;H>#K5->&@@&0`1K5J]HP]O`\LS$U3;F+)OFW4]DU
MI35VLZY3*]2$(T>_,3U&8YQ#_+!QK<^V',R4\I%*\_D^9A76US3#J34VTTIA
M99RFZ6MJ;A10Z-0(_4(0AG8"B$D/:7HMW%#<%/7W)KN9I8<2SV_%A(8(TAOJ
M'IR&&:I3\`!A&K%TC-?L)2ZQ+CF\#>AUIS*M"=>(GDG''F8SL]OTFQ[+X<[#
MUY57`I6N^<=+#4ZTL0XH'&>G]<+QT:3S"B'D`X>N"$$P#\O=G#%KK:>V[L:J
MZHI4PBX:CRTAS/TSG'7=?0U=PVJY249TO+H0!YZ<O7*,:OV_N>/$7B=[8.Q>
M.G*2.CG^Y:#;]HP=MXGVZ(<,[CM)U8IY)>.@$820B%FKYC(`/IU5EP.D@5MT
M,(E[`'I'?^Q=T;Q[N,7S:CH%JJ4!3=:%@!I($YDSGD<QF2)<9:.VCN_;^V=B
M/[=W`A*+LVX0:<HD7IF6$ACB,8K&Y)?6UOYP>W&[Y:Z9AN-OM_V7CC8[/1M'
M;*)'0>H*;L>;;W!^,3=V3%!A2F5G5.O&NO(=$1\I)VD40\SS`RG96*RBV;N%
M&U:I-?W"9K=#SX(4MQH*D5,J5,X`<)S/I'R\Z7]S655[9-'LOZ<+2QB$!:D@
MG6$RF"?6(];Q*V<WMB<TF]<?S(<7X7W$=>(\5I9XM(J0["N?>[F$FG0'4H<0
M/5VR2<8LW\H_IBK"(%#YC9-K<FTT&^;14W$I;OSFV7%529A2]>JFEKRXZL#X
MQ%*PW1>UKDTVMQ5K-]:^GD"$I04U&`'EIQ\!%\?/CC]Q]XK37L[Z]E'TJWTL
M\V=;;ON2=N5DF7ZTX>]CKR8V//V>:3<B]1CI]XNH+M-(2I$;JF('0G7(YL7<
MFX=S6?>ETI^C]R+(0U)*4RDI>@)GAJRQ/&,]N^TVRS5.UZ=8=52N*"G9K/%*
M2KTSPY81Y#1I"\Q[/WQ7/MV`[/QN1KE6+KASJI255J[9^,W'H7D=4#&@9@,@
MC2OO!NC,1.5H5(2]"]F9&O192[L9.^BT-R:BEX*T_*$#3UCD5ZPC'^*<8YE%
MR5_=:]L%P;<49@)G(G69]*>*4RG@.$=FTD;1T3O+V6E.`;NMN-U35?9!R[:Z
MY?O7DV]K)XZN!L9;>S=H=42N$77WH`/*E!9-<A1)^P.6M^1655EWL]O.3=O;
MJM-N)E,A*UA`;P$P$Z3F?/A&1H':8W';*-I#J/BG_P"4@3]JM"9J7/`**ISY
MX3CN_MFZXU9!P_N><V+PRV1=[%QQV5R7JU,K5$L\C&.HJ`M<5.NM@.*NWCE1
M*TN=F9>G1"0.43L`;%5*`B&8ON77W%RW[1V10?2,4-71L/*66T*5U1TRG6HR
M)&)]IS,LHJ;'H6:1>Y-VUG5>K*>H<2A`4I"=!*P4@`&9RQE$?,=/ZX*C[<NV
M=*0O'_4\S+\J8+U$/J>VWW8/)6OQ<E>F+(&G)G;D^_(WD'\THDMY$:HV0461
M.)R@HD4X9/J9%S^KW%:-P.5-:PU;0EK4EM-,5)0".DV%<``=6/QG$/<KK>NG
ML]UMTFNM636@K<6I.I6(5-,I&9`'QX1*;QLU5P_U7[[?)Z@7^HZRHX1C?7UF
MXN5NP`G#@7;T\:NS;Z2ULW6<)>KL,F9Z\5[$_,[Q,IVEZ%$`U5N2][ONO8"V
M+I7UOH;?*:F2L=`ZB0%\=(`3XY3XQL*QVNRVGO#<$5K:4HJ&E%D$>T&:3APY
MRB-TTELI'VX^<0T)>?\`X%=^Z,LPWZXJJK_UK74RC=Z+]*4-&]7B5<4FBM"O
MSB/3Q(0W4AC!FS6V;(K?&W_O-2@+&VBIE15F^66Y(2?RJ&(/$R,0=T75_:-W
M3:>MI;O2>II)3)H.+GAQ$OTRB_>GGU'%^Y%;HGV[W%;5XOO/;RO*_(PFHGRK
M[5*$^6@7):`?3)XXRU?0OPNS0_:<P@\,HHH"H]?,*77SR[E5[!IG=]K5_<2;
MXT*341U2DN@$$Y].6KPD$G&0B8LN-(WHZO:CI59U6E8J"9J"5!L$$$G!4QCX
MD@<HCG'3NL8#V=>(W*B&B!9;Y#F?&4]AM`LS)#/1=497&V%9UZ"7%[Z:*B&J
MT0BN"3<A`]4*B@B)CFZ[6>N-<ONY>-KMA*[=_;J5!J8^?HM%2M4IDXJPY2$0
M-JTM)[96V]K6\;F+VH%P%0!3U7`)HR`D!CSF8SBOXDG?_K//\Y?^3."]+?A'
M6?U%1_J^,63^[1SV8\&>+TQ-5UXV_GELTSVDZ:BE/+77;2ZS8/O%Y6:%.)CQ
ME*C5O4@)OD.].V2'P4'-A]HNWSV]]ULV]X#[+3Z7*A9G+2#/0"!/4J1D,!*>
M(B.]R]XTFS+,IPE1N%2DH:2B15/*9F1@)\/V1A-<`^%.SO<.Y*MM?,'TLE5T
M7@7;>6U'(*/A@*^]D5W<JZ5?K^81Y=+@\.LBP*81.HY.=<P>6D;IW%W'WG:.
MV.ST_2'^:I)0PT)`E,O:2)X8S*I3D!..0]D;1N'<#<J67PDTS3Y==4J<\932
M,#B`,I@8B,P3E)P;J.@:%7KMQVJ"$%K:@5.%JNQ-?0J3A=1"N0"0-H_:,6@4
M%#OIZ&1,(V`1*9:29B+HPF6;]3\:;2[@5]QK':*^/*4]5N:D.+/RF9)3_I!G
M[992EQCK>ML2+&XEVSH";>E(0XA.9!PU\L..,\9^7DG%#>XZ*VPV<2TBE_*;
M:;B(@[L8'!5&%?L;@I(^E;$;B(BFDT<&<)QDJL4>Q5HLU7$PE;&')3OS;/WZ
MV_4M!/WZF3-ODZD8D3`)GQ3AGAQCQ;ZYJTUP>8FJUJ^8C@?']OA$[%RH%)V3
M%(0=_I]6NT2TDF<PWB[7"QMAC4)6.,*C"409RC5TV1D&0J=R2I2]Z8FZE-XY
MSS1W*LMM0I5N<<:?4#,I44S!S$QC*)M56ZEN326+@E+C23J`SDH9''E&Y_+^
MG#;37\*E5PO)H0*R:XA"1Q;2>N%6%P$$:?*T"4^S^>/F>F\T4@/U$"Y[1<;B
M*55O<?=-MZFM+6HZ$KXJTSEJ.&/A%;Z*D;>^M0RT;CH"-9`GI&0G(GGA'56.
MA-,1=:L%+C=2:R84ZV/5)*T51G2:XWK=BD%"@4TA-PR<65A)/A*0@><JF93Y
M`\?`,N7;]?GZY%QJ*VI75M@)0LN*UH0)^T*G.7AE%LW9[6&7:9=,QT'L5#2"
M"KGI(EQSBK1&HM9P(1QH/75"@E8B'6KD2>'J4%'GBZZX*<CF`CU&D>@=G#.B
MJ&\QLGVH'[A$Q1$1RVJ+A<*D=-ZIJ5LES64EQ<BKF1.1(E%1NSV>E45T%,PT
MZI&G4&D!4N6`RSXQ1`X_:3+3D]<AI[5O\NT989]&BA1ZX%11G1,8WWE*N?:Q
MB$Y01.81<`D"G4?CXY<?>[TFM7<T5E3]Q4WHUZU:M/(JG,@\1%/[+9S2"V&E
M9^W`ZM.D2U\Y2EZYQV!KJC7#&T2=W9T"DM[G-PZ==FK8A68="R2]?101;I0<
ME-),BR#Z*30;)IE;JJ&2*1,H`7H`99KKKD[1)M[M2]],E06$ZCIUXS5*<IGG
M%3[=0HJ_K6F&A4%OIJ5+'2,AEB,\XZP/'/0YJLPHYM*ZG-2XF:5LD343T&KF
MK498E>\JD^PA/M(1S.96(<0,Y33*L/4?FRZ^^W]5:JX.5M0:Q3?3U:U:BC^$
MJG,CPRBW:L%E:I44*:5GZ1+FO3I$@O\`B`E*<=@M6H]<WM]792[Z_I%PDJD\
M3?U20LE;B)I[5GJ:K=P#RNNY)BZ<0[GU#1$X';BF8#I$'KU*&6M!6W&TT[]/
M;*E]"*A4UI"R$J)_B`,CF<XN*NWTE>6':MAE533J]BB)D##(RF#AY10W/'K2
M#R*L<$ZT[JMS"7*;2LMQB'%"K"T;:[$W5.NWL%C8GBC-9J9075.<CAR554IC
M"(&`1'+I%ZO390M%6\'FDZ4*U$:48>U..`P&`Y1;&QVHTRV#2LR6Z%J$A(G'
M$X8G&.R*ZJUXO:(*[+T6F*W&K1?V2KVQ2MQ![)6X;RET?M$%-F9C(Q48*+@Y
M/)14(GVG,';XCELBX7-%,Y0FH=-"ZHJ6C40"K@2G(\<3%ZJAH5/HJ0PT*EH2
M0J0U`',3E@,!AE%+/HW4"KVPR#C5.M'#VWND'MM>+T>M+/+,\9J^H9NIYTK%
MF5EEVK@`43,OWB0_S!\WCER+W?%-MM+K*CH-)*4("U:4@\L</(1;BQV5)64T
MS6IQ>I2M(F3CGA'IR#8K9`B"!$DTTB@1%,A>Q)),H`!")IE#M(0H>`%#P`/`
M,Q1;07.ICJS]>,9%E/31H5\HY<H\RF=):GL5K:WN=U;K69N[+RQ9W"6I%;DK
M.V,@(&0%&==Q:LDD9N<H"0P*=2]/#IF51>KZS2JH*6OJFJ!6;:5J"9'/#5+'
MRC&/V.R5M:*RNH:9Q]'R+*$E8/,S3^TQ7;IKBC[&B#P&P*;4KU!&<%=?9;C7
MHFR18.$P[2+D8S#-ZV37`@]H'`O<`?`<MZ&X7*VJZMM?=I:KBMI1!(\9$3GQ
MG%Q56^BK*?H5C+;Z4DE(6`0DG@)@R`X2BGS.H=966ILJ#8]<T*=HL>LT<,:;
M+5*#D:LR7CS",>JTK[I@I$H*,N\WE&*B!B"/4!`1ST+I=VZHUK%4\FO4DA3N
MH]10)!*29SD2`3CP$>%6R@73II54[/TP(.@`:=0$@1AF)G&4\8LNY<\`&?*?
M=O#O;:M[:U"/XH7>2M84X:JA.1UV82!X0HU]<ZK]FA%L@:0WDC^X7*)%!#MZ
M!DOV?ONMVIMZ[V=+?6JKFG2'-6GIXGW2D3,3F)'.(SN395%N2Z6ZMJ#IIZ$D
MZ!QPR'"6&,^$7RU/7U.H,,:O42HU2DP9G3EY]FJ<!%U^(%V\ZBY=GC8IHT:&
M<KF'YSB7N/\``1Z>&0BLK;K<5!ZXU"ZBK$I..$E22,I$DY><2NDH*"B1T*5A
MINFU8I2``H>.$4BH:>UEK^5EYRCZYH%.FK`<ZLY+52H0%=DI=50XJJ'DGT3'
M-73WO6^<?,,;YAZ_'+ZLO-XKJ=-/753]0VV/8EQ:E)2?`$F4_*<6]+9K50N*
M>H:=EETK4=2$@$ZC,A1`&'X1RZMJ^@45&;;TBB4RG-K+(NI>QMJQ78J#0L$L
M\*)74G-)QC%J23D'13"515<%#G*/01$,MJFMKZ\-_<*A]U38`02H^Q(_*DSG
M(2'+*+BEHJ2FZB6F&6T.**EZ4@ZR9_,)#F8H,;H32\(T.PA-/:KAV)YU.SF:
M1M"JS)L-D2`PHV$6S:(32&;0$Y@(Z\%B@/@8,NUW^_+7K-94Z@C1/JKQ1D4G
M'(RQ&,6S-DLS"$I11TI]Y4?Y:!(XF8P.,^.$5>8U%K2Q6J%O=AUY1)V\5LZ2
ME=N4M4X.0M4$=`1,@>*L+IBM+,%&YC&%,R2I.P3#TR@U<[K3TSE#3U3R*!TS
M4T%'IGS3.1]1%6HMMOJ:I%Q<IVC<$"040)R\Y3C57M2ZUJ498(6K:]HU;A[:
M]=R5JBH&K0T7&V21?E['KZ>8M&23:8=.R=2JJ."J'4#P,(Y2=K[G5OM5%;4.
MK<IP`U[U>P#ECAX`91Y9M%MIZ9UAAAM`?7J<`2)+),S/#&<:*KJ36U$B)2OT
MC75"IT#-BY&:AJI5(*NQ4OZLJB;G[HPB8UJV?@X26.4_FE-W`<0'P'%;<+O7
M5"*JIJWW7FR-!6I1*)2,P23C,89<3G'JEMEMHFW$TM+3MES`Z4@!0XZI`?#$
M12#:`TDI3XS7JNGM6GH4+*EGHBDFHM:&IQ4X"JKC[Q'5X8S[4TE`<.#G\\B1
M5>XXFZ]1$<O1?K^FX+NZ*ZJ%T<;Z:G>HK642`*2K5,I($I3E+"*7V>UKI!;U
MTK'T"5!0;"1H"ISG*0`(,R"!G'IOVEC_`.FT_P"@G_V\QO4/(1D>BQRC\^#W
M"-F;E]R[W,IS6&OXYS..H^^/N/VCZ@"QDF$3`UF1<(SUEE#K%*BP:R;]F]EY
M-P(`*#5),HFZ)D*'Z&=N*&T]K>UOWZXA`#R>K4+.G5*0]@,\>(2`?UQQ)O.K
MN/<3>IMU,5]<D"G3C)(GQY<"28S2O;_X.ZWX(<?H#4-,*A+65T*<[M"^^F!M
M(7Z\.6Y"24LL'S*(133J+:/;=PE;M"%#ZS',;A_?V][AO^^N7E9(MRIAE$YZ
M&IDA/GF3XX9".K-D[0HMFVENC0`;BH:G5C\SA`!_5*+W7**2Z*C=8A5$E@\M
M5(Q0,FJB?Y5$E2&`2J)*)B)3%'J!@$0'(>'?S(,EC+SX?C$L(S0L`Z\#Y&(!
M.7'&I/05O$\)&^IT1M)T_95]H")E&]#MDD59W(:V="'X%8L2!5UH,XCT0."C
M(.T"M@-T%LG=OWJD125JA]ZI!-))'O3SGQ,\Q+Q'A!;I:D6I7TK8/VITDJXZ
M3R_=$E?`K9,_L#0[:/M#AS)3NLK'):Q6GG2@*.K#&03"(D:[*OA#ZY0*[,M&
M[P?'N=(*&ZCW9JS>]G1:-PK:;EI5[I<IY^DQ/U,27;U8:ZCUJS29>G"+VP_V
M>&1&,W.<?<0AB$,0AB$,0AB$,0AB$,0AB$,0AB$,0AB$,0AB$,0AB$,0AB$,
M0AB$,0B!?7G`YMQB]X6<Y/1M;6F=0\FJ!>V]?DV<>K($U5OF4/%2MDC)8$&Y
MOL$+?*_%2"T>_./E"Y56:&$ICI]^[KIW`.YNTB-E5$A54#H*A/\`J-X`$<RD
M#W#UY1IVW;+%A[E+W%2B=)6((1(8(5(X'E.>!XQ/"W,`D$"E`H%.8H`'7H(>
M`@/00#IU`?[,T:R@(;`1@W+VCD.4;@2O6I0/SI5(^)PQC=-\/[<.D@`C@1'J
M0(D8LSYXMG,SQHN]<AJE-7BWV>0J$!0JU7FXKRSV\N[5%+5YTFY$AF\*SAUV
MYGKM^L9-%JS;JG,;P`!E.T'*6BW"S7OJ"6$'4LG^$`_M(P^$1N_HJZRU.,4R
M25G`>?\`VCNW%71JVA-31=0DW360M<J_DKA?))CYGH'=QL1VZL@A&^9T$L7"
MLVK>/;>!3*-VA#F`IC&#/.Z[X;_>W+D<$*,DX8Z1E/SQ/K*,E::$VZF#)SPG
M\(N6*'3K^D1'^_(V!*?G&00)#UC5GV/4,0AB$,0AB$,0AB$,0AB$,0AB$,0A
MB$,0AB$,0AB$,0AB$,0AB$,0AB$4YW]'[7U%^GZ/^+_3_/\`IZ8;_JG]!_Y>
M,>*?^J,O7_UCD-OH/\?Q#?']1?A_O_3USZ?TY>GA!&:O]W[!G&^;Z1SRK(Y9
M<8]'(^44M7ZT_K_#5_"^O]GZ_P#2_P`7]F?:?(YYB/=+_P#.?E]8Y2?UE^'T
MG_5^)^S^G\^4'?Z@S]8].QRR_E_7EP8I\!Y1]SY"&(0Q"&(0Q"&(0Q"&(0Q"
=&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"/_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g584757ex99_2logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g584757ex99_2logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`2@#A`P$1``(1`0,1`?_$`+,``0`!`P4!`0``````
M```````)!0@*`@,$!@<!"P$!``$%`0$!``````````````8#!`4'"`(!"1``
M``8"`0($!`$)!0D!`````0(#!`4&``<($1(A$Q0),2(R%3-!46%Q0B,6%PJ!
MD5*28['!@M*3TR1451@1``$"!`0$!`0""0,%`0````$"`P`1!`4A,1(&05$3
M!V%Q@2*1,A05H4+PL<'14B,S%@AB<B3A\8+"-#;_V@`,`P$``A$#$0`_`,Q;
ME#ONT5*P:YX^:53CG._MV2J4?`R$F@,A"ZHI2(K'M&V+*S(<#OQAHEDZ&'8&
M`4Y&43*18Q4"JFR1;;L#-=0OWZOPL=&)IX%:Y3#8)PF<)\ICGA&K]>7J-QJV
MV\`W>J5I5R2DF14?Q_&+FM;T>"UA54:U$JR+LB:[N5FI^;=*2,_9IU^)7$U:
M;+)*%3]7-S3L!67,!2)EZ@1,A$B%*7`U%T<NU5J<3^4!(`DE*!/2E(&0&,AZ
MXDQFV:2FM5-)!]LRI1XE1S/ZH[+&V2O6$CG[!.0\UZ)44'OV>28R8,UR@(BB
M[]$NMZ=4/\)Q*.4U-O,.)2XVKI%4IR.!^$>DU+-0@I;4"2,9$'#CD8CIY,;/
M-P%L$!R$['1N+-YOL?5^1U99MQ<):JL=XE!1@>05:1*=,S.&=61Z1K;VA3"F
MNFX3?HD!PDL5>:;?M#F^D/69'_Z&G;G2Y?S`C-'^X3!;]03*(G?JU&TULW%H
M`6):I/\`-)/YO7&8R_"))(V2CY-BSD(MVVD(^19MY"/?LETW+-\Q=HIN&KQL
MY2,9)=NY06*<ABB)3%,`@/00R$]!]ASZ6J!#[9(((D9@R(/B"#.)>A370^HI
MR%-*D9C+$3'X14R=.@]/RB.>&M7NU?Q'X15``&'&-6580Q"&(0Q"&(0Q"&(0
MQ"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(1`EQ)V4UVES9AMQ3YCKNM
MNQVTGU45=J]Y8J,"%ADZ)","G$00(UU[#+]J)!`OGN')Q`3JJ".^=X6)5EV%
M]GIP2*5Q)=`XE1`).6&J-=6)WZBXHNE1_6?F">0E@$\N7&+A_<HO]F(YUIJ"
M.EI")JUIBK)<+NC%.5V"]I8P+^%BH6L/WS)5!X6OB^ESN7S<IBD>E2324ZIB
M8IHGVPLM'<4U%S*-3K`24!6(!(,\..6'+&,ON*L6*I-M)_XRFP21\V)(S].4
M1@1$C)ZL=EV!K!=M2+E4&JTK%R44B6.9OD(M,7CBO61FU\IG,5V7;(G:KHNB
M*E335$Q!(8I3!NVY4=%<*)5OK*9DI<2`2E,E)G/W).,E)S!X&(Z4+M2354BR
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MC%4@H.WZJ4A(6+>$AME:+M+:&CWK@!310MVM7AXUFF_`@_-#V*+3*F\(/0%X
MY\<0^(#G6R*FCW'2/O/>Z@KV_43&!EP(GZ&-54K;S%O;I$X5U,J:QE\.)RY"
M)?\`85$A.>^E=<[5UU*Q]1V-6@DT&K.QE5691DHX]$RO^K[NE&^8];HI/X]%
M1-PD4RB2J#=P1-1)02GT3:[I6[!O550520:!0"3I.)$U:5#(2D92\\9C&5O4
M2;M1)K&B/J<A/TP/K%NU(]N_<-EG63/;;RFU/7Z#QDI9V]9GGUJL]MBFZP+N
MJW'&/"0K&OLY@J?D.GAC*."H',"293#U"7W_`+I6E%&I5J2^:Q:-`U)"0"9B
M?S$F4Y@<\Y194VVZ^H4*>X*0*2<\%$DRX9#U,0S_`-0KSTC]CW6$X/ZKDFZU
M*U#,,+#N*0CC%%K);'9,S)0%*;"D86R[&D,'?G.B#\H22I4Q#JV'-N_XX]O*
MJVTSN^[PC_GU`G3`GGCJ/(*(20<2`.$XT5WNWM3UKR-DV]1^G;$GR,I92!GC
M(3PPB23^FSU9,5'AEL;9$LQ59-MR;GEI.N"L*X`_K],@XJHDDD$E@Z%;.)QJ
M_(4Q0`#BD(AX=!'6W^2EX17[Z;H]25)HZ8)5+&2BHF7CA(\/QB;]A;4_1[1=
MJ'1)NI>U(YR"98CAG&104``/#.>P04@C*4;T``P'./N?8^PQ"&(0Q"&(0Q"&
M(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(1"O[@NHCTJ^QN\H1ITJ
M^R%8VK;"\A(H-HB_-&H1],LSD.ANQ.WQ@EB'"AR]A7+=GW&#S!$=S=N+PJM0
MYMY2I.-S6B9X<1Z</#RB%WFG1;KNFN`/T[WM4.$_^L>)\7-]?_GK9PNIQWZ3
M4^QWT9$;"3-U]/6;`!TV%9V44#"KY:#8ADXZ9,(]19>2X./_`(@]<SO;:S&X
MK<54R3]UIDE1&6I/*?/`D>/G%"BJ'+?5:EG_`(KCD@.66,79>[9[A47P/XXO
MGU9?,7F^=IMY"M:9AU>QP#)X*!`E]BR#4G<8T%26;DBX"("1P].@B'7N-TAO
M:WMXYO[<J&GYIM-(=3TQ@2)%*)\U2/D)\91:]RM\)V58U/MB=:Z-+>(F)S!5
MSP_3*,#7CGHG9/,/D-2=-U)>3FKUM>Y*C8;*]ZOEXQF[=GDKM?;`J<W>9*-:
MG</5U!']\L`%`>Y0N=_[HW-0;%VR+NXA*;51(D$B0U$#`#S,AZQQEMVUU&\K
MNJC:457:J7/49D`'B>4H_3,T=J.G:!U'K;2]!:@RI^M:?#4^!1[2%56:P[0C
M=5\[$@=%'TBZ!1PN;]I94PCXCGY>7ZXUM]NM5=JM1+KBRLXSQ.0]!(#RCO\`
MM-+2VBW4UKIA)"$`?#,^ICUTGP^(>(B.6B#-`\HR4M)(/$F-?4,]1]AB$.N(
M3$,0CYU#\X?WXA'WKB$Q#J&?)B<N,(9]A#$(8A#&8F,H0Q"&(0Q"&(0Q"&(0
MQ"&(0ZAB$,0AB$,0CHNQJ'6=HTBRZ^N,:64K%MC%X:8:"82*"W<].QTU6`#'
M:R#!P4B[98O0Z#A,BA1`2AE:FJWK?6-U=,9/I4"#RE^S@?"+9YANO94P^/Y1
M'Z?",9_<<&?CQ*[(J&ZG[9!KK>+7E)2QOT#)QESURX;N$X2YM4C]R)OO;<AF
M+QJ3KVRQ540'H9,3=7;;JG=U4C"[:9O/I#93Q0X/FG\1*-95;S5L14.7$A%-
M3@G'\R,TR_&,77D_R6O_`"<V&A<+Q9)N9A:E7D*%K6-GW)G;BIZ[@W#H:]$F
M6*8@.7YVRI3/'`AYSE40\P3"'7.D-K;,L>TK7]"P`E]QP+J%?ZR9@GR,XY%W
M-N.MW;>%URYDHFBG').4OU1F+>P_[=CKC+II?DEM:$*RWEO:':K0\;(-13DM
M=ZF7\I]"P9TU@[F<[:U2DD9$`*!B$].B8.J9PSC3OWW%3N7<"]OVY059:$R4
MH&8<4"9Y&1`E*7!4_".JNT&R/[>M"+O4)E<:H`J!S`_83^KSB1KW!^;49P'T
M2SW=*ZYEMGHOM@5F@(5B#F&4$_,[LY)$Z+PKQ\V=H*`DI']OE@3N.90`#IXY
MK[MSL96_]P)L%-4ADI94[J(U`!)`YCGSB;;XW<QLNR?>WTZU!Q*)><_W1;%"
M>[SJZ8]O6S\^OY=3K5*J7-UKIYIDUCBE+2M?4K4RKK&L(S)&8-1<RC:12?%$
M6X&!'N#M$0S/N]G[G2[^;V4:D%QQCZCJ2]H;4#[B)\"F4I\?.,0ON;:U[/7O
M!I@K0VM36GCKD"1Y2CV;VZ_<,KGN`:JV+M5KK69TW'ZZOR]&E(VU66,F%5%T
M82-FG$HN];-HYO'MT"R'E&(H'4IR"/7,/W&[>W'8%_:L:JD/U#["'$Z4$@ZR
M0$A,R9F47NP]]TN]K,N^*:33L-J"25D8%(/APG%^-?OM%N"#Q[4;E5K4S8*F
M;R+FN6")FF[!4@&,9-XI'O%TVJI2@(_.)1Z9!:REK:)Y#%4TZPXL^W6V0%*Y
M`G&?A*)72W"DJ&BY3/,+IT$J*M6(]`(V5-C:\1<0K)2[TY)U8U54:\S&S017
M,\LW4%)=*&0^X>9*G15*)#%1`XE.`@/CGT6:[)#A+;I6A6H_RE32.9'#S,H^
MBOM+<DAZG#*_:/<,3R$<F2O-(@"2AYJW5F"+"MT'TT:8GHF,"&9.S@FU=RH/
M'J(QK9RH(%3.MV%.80`/'+9JEK:I`>HT+DL_-TYZIYC/$CC%=VJHZ4])QQD*
M;0)@J`D,9$\ARBQ7GS[A%4X+:RU;M->B/=O0FT=E0^O(M.K6>'C$FH3+%T_;
MSZ<FLA(,I".*1J(=J0AW]>O=X#D[V)L&KWI75MJ2Z:>HH*5=2H*;()#9`(E,
M9ZA*<0_>V\Z?:M!37!*6WZ2I?0R-)_,N<CQPP,XYA^>419N<##A-JK6LOLN=
MK]-0NN^-CQMA81]0T8T>D!2*@I\#-G2\[9I$JR0$9HG2.0[@G?T`#B0O8]11
M[*.[KG5):0JJ*&&R/>Y+-0Q$DCP!F,<(^#>=-5;E&V:&G+KCC`6ZX):43X'Q
M'ICA'8>+'-!#D1+<B&-HU?+Z2CM";45U@WGKK9H1:.V!Y;B1:)6.%<)@T3CF
M;A6.`I$%CG6$RI0^.6^XMF.6(6VKIG/JJFX4G6TH:.H`A)EF9RGGA'O;^YS=
M55].^VJF8H7NGJ+F!S&>$LHO"C;C4)67DZ]$6B`EIV%[/O,)&S<9(3$1YW:*
M8RD8U=JOF(*@8.WS4R]>OZ0R'.,UGT_U[S3U.T!I"G&R!,RRQ(X93B4LU-.I
M:J1#S;KND$IU:ER.1\N461\\O<"H'"#3SS:2D&UV[)Q.P:70IV@UBY5^,L4"
MI<EGJ;68F$EQ?KQK)IZ$1$BJ)15[@`HY--C;!O&[KA]K`4EU-(X]U.F0@I24
M`@8@3.H2,\@8B^[=[6[:U"BO*VE(#Z62@$:PI8,ICD-)G%\[*QL%*JRM3\Z,
M7&N(!&Q/5G*R9&T8Q5C2RCE9VY,)4B(,VYC"=0>A0`HCX!D.>IU?6BB2@K=4
MYTP!Q,Y`>IB5LO)-%]<2$M],.&?(B9^$06V3WV:45O>]DZLXD<B]O<6=76;^
M&+_R:K36!C:C'N4W*#15]%PTDH22D8I,SE)3SE%&_P"Z53,<$P.7KNZA[$7)
ME]NT76YTE+N5YN;-"9E02!.1D1(@"6`5D>4:B?[PT*7G;A:[<]46)E>EZI&4
MR<P)&?QB86B<A-/;`U!3=ZPU\KC?5M_@(BS5JUSLJPK[!PPFTBJ-D7*TNY:)
MLI)-4115;G-WI+$,0>H@.:?N%AN]JNM197*=]5:TLI6AL:E(4,SAP.!!C:%+
M?K356YJ\4M0GZ!T!25+,@0K\OFG(\H](6ME92C&<XM88-&"?E0]!+KRT>G%O
M0="4&@M'YG/HW(.!_#[#F%01^7KE@BFJEK+/2?34M`DH4@E>$AJ(SPGF><7J
MZBB%&:U;S1869!9(T8XZ9\\/PC8)=J6JH1,EKK:AEGK^-2[9Z*-ZB1BRB:2C
MDQ*[$5'L83Q<(_6@'U@7*B**M=<=9;9=);2%+DV<-64^1/Z&*;U?;V@AQ3M.
M`\-*9J&,N7,1OURV5>VQ_P!WJM@@[-%@NNU&3@)6.FXT'+4>UPCZZ-=.6P+-
MS]2G+W=Q3`("&4JFGK:/2AYMULG\JTD+5/E./K552U#?\M;3FC\R2"E/GRCB
M05]H]I=2<=6[A6;%)0JWD3#"#L$3+OXA?J4/3R+2/>.'#%7N,`=JA2CU'I\<
MJU-KKJ1`55,U*&W`"-25)EA,9RSCTU64KX"FG:=;LR`4J!G+/X<8WFERJ+]X
MBPCK-77[]RZ?,V[%C.1;EZZ=1:7FR;5%L@[.NNXC4S`=P0"B9$H]3@4,I*I:
ME+(>4VZW3ID"I:3I(.4CB)DC`Q[:J:!;Q;8=8-3^8!0)!S.6,<%KL;7\E..*
MI'7BHR%K:`87588V:&=V!N4`$>Y>&0>GD42@7YNIDP`"^/PRJ]0W-IKZHLO-
M4:9%3BVCI(.6/CP,4&;C;Z@I:6\QK6HI$E"<Q.<O$2BS[7_N":1V+R^V9P[A
MGB*5MUE5*W85;J[LU5/4+?(651FFA4::=&56?S5D8`['U*!"=R1DS%$O7)=<
M=@7:W[79W>Y,,U;FC1TU30/=)2I@`"2<_$1&+9O2W5>XJK:[8<U4R20Z7`=9
M$L/Q\<HK/#KF.MRKAMS3LUJ.?TJVU%M.<USUN$[$R!;.QA43+#<&KAFBW2C8
MIV7Z2JB)R^(B;/.[]H#:;UOI6ZDU3]PIDN@!L@S*0K1*9G*>8Y91[VKNA&X4
MUM2^S]*W2O%LZE3U"9`43(2G*+L8"\TJULG4K5;76K/%L%'#9](5Z<BYE@R6
M;&'U"3QZP=KMVQT.T1.4Y@$O0>OPR(U-+7424BL:<8<4?:E39!SE,`RGG$GI
M:NAK5+;IGVUH1\R9C`<XV?YBZ_%W"QP7:H#(6/S35V._B6$%Y/E;G$BYH5H#
MX5I4J"A1*84"J`!@Z?'*B[3=4E3G3<UH3-7\HS`\>6'./`N5J6E*.LP6U+*1
M[ABH$Y<\H[QU']/^7+76C^$_"+W2Y_$(XZ@F*F/CX]0#P#QZ]!^'C\>O3*;K
MS=.@U2`5?C/RCXVT'4!I9E+/&485']0QS?IVV=M0'%G681C]+2AI#^:U\8`!
MG;^V28,ERZN:/D#^6Y@ZT+9)U)I'$Q/N@I%Z`9!3KW)_C?L*XVFV.;RN15TJ
MPD--G\J0,')<U3P\!')/?3?%#6U#>V[<J263[U#\QGBB?&4OB8C3]OSC1+;#
MNT?O"58QIJ;J^R,)2LQU@:(R,#?+Y7GC*3:UZ4:+D5*ZK#!RF4DF<`\#&(F7
MYNN;>WS>Z>BMCVW6%ZJVN96@N`_(5C3.?!0G,'A$5[:[-J;[5&_NIT6^D(.@
MX$JS2?\`;AB.,?H1:!W-6M\:NK>Q*Z06/W!$S&P5Y=9([^HVR-[4+%5),J9A
M*1["O@,3J``59'RUB?NU"CGYJWRS56W[D[::R9>0HD$F>L3SF<Y\X[/L]P9N
M-('6I"6!`$I$<)</W2B(O^H$6!OPSUF=4Z:7;R[T$9(Z@@4OF?=Y8Q.X!_$+
MW%\0#XAUS<7^/:J.FWNXM?L;%N?$\C,%$L?4QJWO6RX[M5II*=8<NC0(E/V$
M&<N7G$13#CKL!+W5[)[<"*1@XXR?*R*Y\24:5$YFYZG$49Y98QH=,@`U^SJ3
MLB2/$1#L%X@0GQ#-M5-[H'>V3/<QPC^Z$TXMH<P!4J9#DTYS'M*5SPF2!C&K
MVK5=V=Y.['1-.W'%JJ=&G\L@4$*\@J?/#E'ANEMP:YUQ[67+E/9-`L^S8#8?
MN$A3B0=<V)8=95EG*K0",LV?;*N%71<RK:A-CQ_1=D!0%Z<"%ZEZ`8,Y=[?<
M[CWEM[UK6Q3/HL"5A3R$5!T(40=`60`Z9X+S'J8LK164]J[<5S%P;=6E-T`2
ME"E-`$@R4LI!*D"6*<CZ1<SPW&#J_NC7JO:]D-`1U.L_`[8[V9B.):5EC-!2
M\M$U5D94(TT[,2B=RL,$[.!7DJB84S+B)?E4*J&0W>+S]7VFIWJY58JO:OF*
MZ@H4X05I`(`/L$L@!E('C$CVLEL]T'443S+EJ-I*ND@J#864JGJ!3)7C/+$B
M+%T=,:O9>R9KOE*A#B3>D'S/;5&O;*-.RIYBM5E.:D!+7*_WOQ80\8=RB#DZ
M;=-,5'0BJ83&$<V6NZN5/>NLVWU$_P!ON[?6M:9C^J)24%2F,R)`REPB$HH0
M.U3=_>+OW1N\Z$$3_I\BG(X<8E4E])ZJY(>\-S<INZ:^G?:NSX.4*YA6Y.6D
M48ES9H_7M$",GI*-9/&[>2>Q*KY5PT,N4Y6[D_G$`#]!S3S%ZK]O]FZ!ZUJ0
MW7B_.`F22=&M0*<0?:9`2Y3E*<;*%+3WK?MPH*[6JW*LZ%)`)29A*I&8XB9/
MB93B+>[34U(>QQQ)(WFUGDA%\\KQ!50[^3\Y*.\B+G582.:K.3J%19,Y-SW$
M2#J5,#&Z!T\,W&TW;:?_`""NAF!;';`5N#4`%`J3J$^9EARC6M?4/U79VWK3
MK57)O(0#I)((3@?(`Q*+P68[0]KWW*F/'3D9=B72#Y\T"MW)#:+TK9`LOOE,
M'C]VS&555%XOV6!T_AB`<_1P5RR4`@=W0-2;_59>Z/;<;CL+70J+!6+;+*5`
M#I$2U%`$B=*-0^$;"V6BMV'O5%DO#BG1>*=*TND'YACI"CEBJ1$1Z;*>(H\'
M_>@6(Z2251]QO7Q_/!5(AT%BWR?$IA4Z_NEBG*`AU\0$/#QR?[?J*5.ZMFJ6
MJ33>W%:Y+E)>EB?EPPB)5JC_`&UN3ISUO7I($DXZ)NY?OB_8^HJKQO\`=<X4
MQO&F"+3[1MK@=?;99$6DQ*NW>P=B.M;7Q=E,VI60>NW$Y(24S'M%%5E1.85D
MR"`!VAT@#-ZKMS=M+M4;H>#K5->&@@&0`1K5J]HP]O`\LS$U3;F+)OFW4]DU
MI35VLZY3*]2$(T>_,3U&8YQ#_+!QK<^V',R4\I%*\_D^9A76US3#J34VTTIA
M99RFZ6MJ;A10Z-0(_4(0AG8"B$D/:7HMW%#<%/7W)KN9I8<2SV_%A(8(TAOJ
M'IR&&:I3\`!A&K%TC-?L)2ZQ+CF\#>AUIS*M"=>(GDG''F8SL]OTFQ[+X<[#
MUY57`I6N^<=+#4ZTL0XH'&>G]<+QT:3S"B'D`X>N"$$P#\O=G#%KK:>V[L:J
MZHI4PBX:CRTAS/TSG'7=?0U=PVJY249TO+H0!YZ<O7*,:OV_N>/$7B=[8.Q>
M.G*2.CG^Y:#;]HP=MXGVZ(<,[CM)U8IY)>.@$820B%FKYC(`/IU5EP.D@5MT
M,(E[`'I'?^Q=T;Q[N,7S:CH%JJ4!3=:%@!I($YDSGD<QF2)<9:.VCN_;^V=B
M/[=W`A*+LVX0:<HD7IF6$ACB,8K&Y)?6UOYP>W&[Y:Z9AN-OM_V7CC8[/1M'
M;*)'0>H*;L>;;W!^,3=V3%!A2F5G5.O&NO(=$1\I)VD40\SS`RG96*RBV;N%
M&U:I-?W"9K=#SX(4MQH*D5,J5,X`<)S/I'R\Z7]S655[9-'LOZ<+2QB$!:D@
MG6$RF"?6(];Q*V<WMB<TF]<?S(<7X7W$=>(\5I9XM(J0["N?>[F$FG0'4H<0
M/5VR2<8LW\H_IBK"(%#YC9-K<FTT&^;14W$I;OSFV7%529A2]>JFEKRXZL#X
MQ%*PW1>UKDTVMQ5K-]:^GD"$I04U&`'EIQ\!%\?/CC]Q]XK37L[Z]E'TJWTL
M\V=;;ON2=N5DF7ZTX>]CKR8V//V>:3<B]1CI]XNH+M-(2I$;JF('0G7(YL7<
MFX=S6?>ETI^C]R+(0U)*4RDI>@)GAJRQ/&,]N^TVRS5.UZ=8=52N*"G9K/%*
M2KTSPY81Y#1I"\Q[/WQ7/MV`[/QN1KE6+KASJI255J[9^,W'H7D=4#&@9@,@
MC2OO!NC,1.5H5(2]"]F9&O192[L9.^BT-R:BEX*T_*$#3UCD5ZPC'^*<8YE%
MR5_=:]L%P;<49@)G(G69]*>*4RG@.$=FTD;1T3O+V6E.`;NMN-U35?9!R[:Z
MY?O7DV]K)XZN!L9;>S=H=42N$77WH`/*E!9-<A1)^P.6M^1655EWL]O.3=O;
MJM-N)E,A*UA`;P$P$Z3F?/A&1H':8W';*-I#J/BG_P"4@3]JM"9J7/`**ISY
MX3CN_MFZXU9!P_N><V+PRV1=[%QQV5R7JU,K5$L\C&.HJ`M<5.NM@.*NWCE1
M*TN=F9>G1"0.43L`;%5*`B&8ON77W%RW[1V10?2,4-71L/*66T*5U1TRG6HR
M)&)]IS,LHJ;'H6:1>Y-VUG5>K*>H<2A`4I"=!*P4@`&9RQE$?,=/ZX*C[<NV
M=*0O'_4\S+\J8+U$/J>VWW8/)6OQ<E>F+(&G)G;D^_(WD'\THDMY$:HV0461
M.)R@HD4X9/J9%S^KW%:-P.5-:PU;0EK4EM-,5)0".DV%<``=6/QG$/<KK>NG
ML]UMTFNM636@K<6I.I6(5-,I&9`'QX1*;QLU5P_U7[[?)Z@7^HZRHX1C?7UF
MXN5NP`G#@7;T\:NS;Z2ULW6<)>KL,F9Z\5[$_,[Q,IVEZ%$`U5N2][ONO8"V
M+I7UOH;?*:F2L=`ZB0%\=(`3XY3XQL*QVNRVGO#<$5K:4HJ&E%D$>T&:3APY
MRB-TTELI'VX^<0T)>?\`X%=^Z,LPWZXJJK_UK74RC=Z+]*4-&]7B5<4FBM"O
MSB/3Q(0W4AC!FS6V;(K?&W_O-2@+&VBIE15F^66Y(2?RJ&(/$R,0=T75_:-W
M3:>MI;O2>II)3)H.+GAQ$OTRB_>GGU'%^Y%;HGV[W%;5XOO/;RO*_(PFHGRK
M[5*$^6@7):`?3)XXRU?0OPNS0_:<P@\,HHH"H]?,*77SR[E5[!IG=]K5_<2;
MXT*341U2DN@$$Y].6KPD$G&0B8LN-(WHZO:CI59U6E8J"9J"5!L$$$G!4QCX
MD@<HCG'3NL8#V=>(W*B&B!9;Y#F?&4]AM`LS)#/1=497&V%9UZ"7%[Z:*B&J
MT0BN"3<A`]4*B@B)CFZ[6>N-<ONY>-KMA*[=_;J5!J8^?HM%2M4IDXJPY2$0
M-JTM)[96V]K6\;F+VH%P%0!3U7`)HR`D!CSF8SBOXDG?_K//\Y?^3."]+?A'
M6?U%1_J^,63^[1SV8\&>+TQ-5UXV_GELTSVDZ:BE/+77;2ZS8/O%Y6:%.)CQ
ME*C5O4@)OD.].V2'P4'-A]HNWSV]]ULV]X#[+3Z7*A9G+2#/0"!/4J1D,!*>
M(B.]R]XTFS+,IPE1N%2DH:2B15/*9F1@)\/V1A-<`^%.SO<.Y*MM?,'TLE5T
M7@7;>6U'(*/A@*^]D5W<JZ5?K^81Y=+@\.LBP*81.HY.=<P>6D;IW%W'WG:.
MV.ST_2'^:I)0PT)`E,O:2)X8S*I3D!..0]D;1N'<#<J67PDTS3Y==4J<\932
M,#B`,I@8B,P3E)P;J.@:%7KMQVJ"$%K:@5.%JNQ-?0J3A=1"N0"0-H_:,6@4
M%#OIZ&1,(V`1*9:29B+HPF6;]3\:;2[@5]QK':*^/*4]5N:D.+/RF9)3_I!G
M[992EQCK>ML2+&XEVSH";>E(0XA.9!PU\L..,\9^7DG%#>XZ*VPV<2TBE_*;
M:;B(@[L8'!5&%?L;@I(^E;$;B(BFDT<&<)QDJL4>Q5HLU7$PE;&')3OS;/WZ
MV_4M!/WZF3-ODZD8D3`)GQ3AGAQCQ;ZYJTUP>8FJUJ^8C@?']OA$[%RH%)V3
M%(0=_I]6NT2TDF<PWB[7"QMAC4)6.,*C"409RC5TV1D&0J=R2I2]Z8FZE-XY
MSS1W*LMM0I5N<<:?4#,I44S!S$QC*)M56ZEN326+@E+C23J`SDH9''E&Y_+^
MG#;37\*E5PO)H0*R:XA"1Q;2>N%6%P$$:?*T"4^S^>/F>F\T4@/U$"Y[1<;B
M*55O<?=-MZFM+6HZ$KXJTSEJ.&/A%;Z*D;>^M0RT;CH"-9`GI&0G(GGA'56.
MA-,1=:L%+C=2:R84ZV/5)*T51G2:XWK=BD%"@4TA-PR<65A)/A*0@><JF93Y
M`\?`,N7;]?GZY%QJ*VI75M@)0LN*UH0)^T*G.7AE%LW9[6&7:9=,QT'L5#2"
M"KGI(EQSBK1&HM9P(1QH/75"@E8B'6KD2>'J4%'GBZZX*<CF`CU&D>@=G#.B
MJ&\QLGVH'[A$Q1$1RVJ+A<*D=-ZIJ5LES64EQ<BKF1.1(E%1NSV>E45T%,PT
MZI&G4&D!4N6`RSXQ1`X_:3+3D]<AI[5O\NT989]&BA1ZX%11G1,8WWE*N?:Q
MB$Y01.81<`D"G4?CXY<?>[TFM7<T5E3]Q4WHUZU:M/(JG,@\1%/[+9S2"V&E
M9^W`ZM.D2U\Y2EZYQV!KJC7#&T2=W9T"DM[G-PZ==FK8A68="R2]?101;I0<
ME-),BR#Z*30;)IE;JJ&2*1,H`7H`99KKKD[1)M[M2]],E06$ZCIUXS5*<IGG
M%3[=0HJ_K6F&A4%OIJ5+'2,AEB,\XZP/'/0YJLPHYM*ZG-2XF:5LD343T&KF
MK498E>\JD^PA/M(1S.96(<0,Y33*L/4?FRZ^^W]5:JX.5M0:Q3?3U:U:BC^$
MJG,CPRBW:L%E:I44*:5GZ1+FO3I$@O\`B`E*<=@M6H]<WM]792[Z_I%PDJD\
M3?U20LE;B)I[5GJ:K=P#RNNY)BZ<0[GU#1$X';BF8#I$'KU*&6M!6W&TT[]/
M;*E]"*A4UI"R$J)_B`,CF<XN*NWTE>6':MAE533J]BB)D##(RF#AY10W/'K2
M#R*L<$ZT[JMS"7*;2LMQB'%"K"T;:[$W5.NWL%C8GBC-9J9075.<CAR554IC
M"(&`1'+I%ZO390M%6\'FDZ4*U$:48>U..`P&`Y1;&QVHTRV#2LR6Z%J$A(G'
M$X8G&.R*ZJUXO:(*[+T6F*W&K1?V2KVQ2MQ![)6X;RET?M$%-F9C(Q48*+@Y
M/)14(GVG,';XCELBX7-%,Y0FH=-"ZHJ6C40"K@2G(\<3%ZJAH5/HJ0PT*EH2
M0J0U`',3E@,!AE%+/HW4"KVPR#C5.M'#VWND'MM>+T>M+/+,\9J^H9NIYTK%
MF5EEVK@`43,OWB0_S!\WCER+W?%-MM+K*CH-)*4("U:4@\L</(1;BQV5)64T
MS6IQ>I2M(F3CGA'IR#8K9`B"!$DTTB@1%,A>Q)),H`!")IE#M(0H>`%#P`/`
M,Q1;07.ICJS]>,9%E/31H5\HY<H\RF=):GL5K:WN=U;K69N[+RQ9W"6I%;DK
M.V,@(&0%&==Q:LDD9N<H"0P*=2]/#IF51>KZS2JH*6OJFJ!6;:5J"9'/#5+'
MRC&/V.R5M:*RNH:9Q]'R+*$E8/,S3^TQ7;IKBC[&B#P&P*;4KU!&<%=?9;C7
MHFR18.$P[2+D8S#-ZV37`@]H'`O<`?`<MZ&X7*VJZMM?=I:KBMI1!(\9$3GQ
MG%Q56^BK*?H5C+;Z4DE(6`0DG@)@R`X2BGS.H=966ILJ#8]<T*=HL>LT<,:;
M+5*#D:LR7CS",>JTK[I@I$H*,N\WE&*B!B"/4!`1ST+I=VZHUK%4\FO4DA3N
MH]10)!*29SD2`3CP$>%6R@73II54[/TP(.@`:=0$@1AF)G&4\8LNY<\`&?*?
M=O#O;:M[:U"/XH7>2M84X:JA.1UV82!X0HU]<ZK]FA%L@:0WDC^X7*)%!#MZ
M!DOV?ONMVIMZ[V=+?6JKFG2'-6GIXGW2D3,3F)'.(SN395%N2Z6ZMJ#IIZ$D
MZ!QPR'"6&,^$7RU/7U.H,,:O42HU2DP9G3EY]FJ<!%U^(%V\ZBY=GC8IHT:&
M<KF'YSB7N/\``1Z>&0BLK;K<5!ZXU"ZBK$I..$E22,I$DY><2NDH*"B1T*5A
MINFU8I2``H>.$4BH:>UEK^5EYRCZYH%.FK`<ZLY+52H0%=DI=50XJJ'DGT3'
M-73WO6^<?,,;YAZ_'+ZLO-XKJ=-/753]0VV/8EQ:E)2?`$F4_*<6]+9K50N*
M>H:=EETK4=2$@$ZC,A1`&'X1RZMJ^@45&;;TBB4RG-K+(NI>QMJQ78J#0L$L
M\*)74G-)QC%J23D'13"515<%#G*/01$,MJFMKZ\-_<*A]U38`02H^Q(_*DSG
M(2'+*+BEHJ2FZB6F&6T.**EZ4@ZR9_,)#F8H,;H32\(T.PA-/:KAV)YU.SF:
M1M"JS)L-D2`PHV$6S:(32&;0$Y@(Z\%B@/@8,NUW^_+7K-94Z@C1/JKQ1D4G
M'(RQ&,6S-DLS"$I11TI]Y4?Y:!(XF8P.,^.$5>8U%K2Q6J%O=AUY1)V\5LZ2
ME=N4M4X.0M4$=`1,@>*L+IBM+,%&YC&%,R2I.P3#TR@U<[K3TSE#3U3R*!TS
M4T%'IGS3.1]1%6HMMOJ:I%Q<IVC<$"040)R\Y3C57M2ZUJ498(6K:]HU;A[:
M]=R5JBH&K0T7&V21?E['KZ>8M&23:8=.R=2JJ."J'4#P,(Y2=K[G5OM5%;4.
MK<IP`U[U>P#ECAX`91Y9M%MIZ9UAAAM`?7J<`2)+),S/#&<:*KJ36U$B)2OT
MC75"IT#-BY&:AJI5(*NQ4OZLJB;G[HPB8UJV?@X26.4_FE-W`<0'P'%;<+O7
M5"*JIJWW7FR-!6I1*)2,P23C,89<3G'JEMEMHFW$TM+3MES`Z4@!0XZI`?#$
M12#:`TDI3XS7JNGM6GH4+*EGHBDFHM:&IQ4X"JKC[Q'5X8S[4TE`<.#G\\B1
M5>XXFZ]1$<O1?K^FX+NZ*ZJ%T<;Z:G>HK642`*2K5,I($I3E+"*7V>UKI!;U
MTK'T"5!0;"1H"ISG*0`(,R"!G'IOVEC_`.FT_P"@G_V\QO4/(1D>BQRC\^#W
M"-F;E]R[W,IS6&OXYS..H^^/N/VCZ@"QDF$3`UF1<(SUEE#K%*BP:R;]F]EY
M-P(`*#5),HFZ)D*'Z&=N*&T]K>UOWZXA`#R>K4+.G5*0]@,\>(2`?UQQ)O.K
MN/<3>IMU,5]<D"G3C)(GQY<"28S2O;_X.ZWX(<?H#4-,*A+65T*<[M"^^F!M
M(7Z\.6Y"24LL'S*(133J+:/;=PE;M"%#ZS',;A_?V][AO^^N7E9(MRIAE$YZ
M&IDA/GF3XX9".K-D[0HMFVENC0`;BH:G5C\SA`!_5*+W7**2Z*C=8A5$E@\M
M5(Q0,FJB?Y5$E2&`2J)*)B)3%'J!@$0'(>'?S(,EC+SX?C$L(S0L`Z\#Y&(!
M.7'&I/05O$\)&^IT1M)T_95]H")E&]#MDD59W(:V="'X%8L2!5UH,XCT0."C
M(.T"M@-T%LG=OWJD125JA]ZI!-))'O3SGQ,\Q+Q'A!;I:D6I7TK8/VITDJXZ
M3R_=$E?`K9,_L#0[:/M#AS)3NLK'):Q6GG2@*.K#&03"(D:[*OA#ZY0*[,M&
M[P?'N=(*&ZCW9JS>]G1:-PK:;EI5[I<IY^DQ/U,27;U8:ZCUJS29>G"+VP_V
M>&1&,W.<?<0AB$,0AB$,0AB$,0AB$,0AB$,0AB$,0AB$,0AB$,0AB$,0AB$,
M0AB$,0B!?7G`YMQB]X6<Y/1M;6F=0\FJ!>V]?DV<>K($U5OF4/%2MDC)8$&Y
MOL$+?*_%2"T>_./E"Y56:&$ICI]^[KIW`.YNTB-E5$A54#H*A/\`J-X`$<RD
M#W#UY1IVW;+%A[E+W%2B=)6((1(8(5(X'E.>!XQ/"W,`D$"E`H%.8H`'7H(>
M`@/00#IU`?[,T:R@(;`1@W+VCD.4;@2O6I0/SI5(^)PQC=-\/[<.D@`C@1'J
M0(D8LSYXMG,SQHN]<AJE-7BWV>0J$!0JU7FXKRSV\N[5%+5YTFY$AF\*SAUV
MYGKM^L9-%JS;JG,;P`!E.T'*6BW"S7OJ"6$'4LG^$`_M(P^$1N_HJZRU.,4R
M25G`>?\`VCNW%71JVA-31=0DW360M<J_DKA?))CYGH'=QL1VZL@A&^9T$L7"
MLVK>/;>!3*-VA#F`IC&#/.Z[X;_>W+D<$*,DX8Z1E/SQ/K*,E::$VZF#)SPG
M\(N6*'3K^D1'^_(V!*?G&00)#UC5GV/4,0AB$,0AB$,0AB$,0AB$,0AB$,0A
MB$,0AB$,0AB$,0AB$,0AB$,0AB$4YW]'[7U%^GZ/^+_3_/\`IZ8;_JG]!_Y>
M,>*?^J,O7_UCD-OH/\?Q#?']1?A_O_3USZ?TY>GA!&:O]W[!G&^;Z1SRK(Y9
M<8]'(^44M7ZT_K_#5_"^O]GZ_P#2_P`7]F?:?(YYB/=+_P#.?E]8Y2?UE^'T
MG_5^)^S^G\^4'?Z@S]8].QRR_E_7EP8I\!Y1]SY"&(0Q"&(0Q"&(0Q"&(0Q"
=&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"/_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
